The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
**Field of invention**

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases where activation of CCR2 plays a causative role, especially pulmonary diseases like asthma and COPD, neurologic disease, especially pain diseases, immune related diseases, especially diabetes mellitus including diabetes nephropathy, and cardiovascular diseases, especially atherosclerotic disease.

**Background of the invention**

The chemokines are a family of small, proinflammatory cytokines, with potent chemotactic activities. Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract various cells, such as monocytes, macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation.

Chemokine receptors, such as CCR2 or CCR5 have been implicated as being important mediators of inflammatory and immunoregulatory disorders and diseases as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. Accordingly, agents which modulate chemokine receptors such as the CCR2 and CCR5 receptor would be useful in such disorders and diseases.

In particular it is widely accepted that numerous conditions and diseases involve inflammatory processes. Such inflammations are critically triggered and / or promoted by the activity of macrophages, which are formed by differentiation out of monocytes. It has further been found that monocytes are characterized by, e.g., a high expression of membrane-resident CCR2, whereas the CCR2 expression in macrophages is lower. CCR2 is a critical regulator of monocytes trafficking, which can be described as the movement of the monocytes towards an inflammation along a gradient of monocyte chemoattractant proteins (MCP-1, MCP-2, MCP-3, MCP-4).

Therefore, in order to reduce macrophage-induced inflammation, it would be desirable to block the monocyte CCR2 by an antagonist, so that the monocytes can be less triggered to move towards an inflammation area for conversion into macrophages.

Based on the aforesaid there is a need for providing effective antagonists for CCR2, which are pharmacologically acceptable.
Description of the invention

It has now been found that such effective CCR2 inhibitors can be provided by compounds according to general formula (I),

\[
\begin{align*}
&\text{with } A \text{ being a group selected from among } -\text{NH-L}_1\text{-R}_7, -\text{NCH}_3\text{-L}_1\text{-R}_7, -\text{O-L}_1\text{-R}_7, \text{ and the } \\
&\text{structure (II)}
\end{align*}
\]

wherein A is a group selected from among -NH-L_1-R_7, -NCH_3-L_1-R_7, -O-L_1-R_7, and the structure (II)

wherein R_7 is a ring selected from among -C_3-C_8-cycloalkyl, -C_3-Cs-heterocyclyl, -Cs-C_{10}-aryl, and -Cs-Cio-heteroaryl,

wherein the ring R_7 is optionally substituted with one or more groups selected from among -CF_3, -Ci-Cg-alkyl, -0-CF_3, -CN, -O-Ci-Cg-alkyl, -Ci-Cg-alkenyl, and -Ci-Cg-alkynyl, and -halogen,

or wherein the ring R_7 is optionally substituted with one or more groups selected from among -C_5-Cio-aryl, -Cs-Cio-heteroaryl, -C_3-C_8-cycloalkyl, -C_3-C_8-heterocyclyl, optionally being substituted by one or more groups selected from among -OH, -NH_2, -Ci-C_4-alkyl, -0-Ci-C_6-alkyl, -CN, -CF_3, -OCF_3, halogen, and =0,

or wherein the ring R_7 is optionally further bi-valently substituted on two neighbouring ring atoms, such that an annelated ring is formed by one or more groups selected from among -Ci-C_6-alkylene, -C_2-C_6-alkylene and -C_4-C_6-alkynylene, in which one or two carbon centers may optionally be replaced by 1 or 2 hetero atoms selected from N, O and S, the bivalent group being optionally substituted by one or more groups selected from -OH, -NH_2, -Ci-C_3-alkyl, -O-Ci-Cg-alkyl, -CN, -CF_3, -OCF_3, halogen, and =0;

wherein R_6 is selected from among -H, -halogen, -CN, -0-Ci-C_4-alkyl, -Ci-C_4-alkyl, -CH=CH_2, -C=CH, -CF_3, -OCF_3, -OCF_2_H, and -OCFH_2;

wherein R_2 is selected from among -H, -halogen, -CN, -0-Ci-C_4-alkyl, -Ci-C_4-alkyl, -CH=CH_2, -C=CH, -cyclopropyl, -CF_3, -OCF_3, -OCF_2_H, and -OCFH_2;
wherein \( R_3 \) is selected from among -H, -methyl, -ethyl, -propyl, -i-propyl, -cyclopropyl, -OCH\(_3\), -OH, and -CN;

wherein \( Z \) is C or N;

wherein \( R_i \) is selected from among -H, -Ci-C\(_4\)-alkyl, -OH, -O-Ci-C\(_4\)-alkyl, -halogen, -CN, -CF\(_3\), and -OCF\(_3\);

wherein \( n \) is 1, 2 or 3;

wherein \( R_4 \) and \( R_5 \) are independently selected from among an electron pair, -H, and a group selected from among -Ci-C\(_6\)-alkyl, -NH\(_2\), -C\(_3\)-C\(_8\)-cycloalkyl, -C\(_3\)-C\(_8\)-heterocyclyl, -C\(_5\)-C\(_10\)-aryl, -Cs-Cio-heteroaryl, and -C(0)-N(R\(_8\),R\(_s\)), with \( R_8 \) and \( R_s \) independently being selected from among -H, and -Ci-C\(_6\)-alkyl,

and wherein \( R_4 \) and \( R_5 \) if different from an electron pair or -H are optionally independently substituted with one or more groups selected from among -halogen, -OH, -CF\(_3\), -CN, -Ci-C\(_6\)-alkyl, -O-Ci-C\(_6\)-alkyl, -0-C\(_3\)-C\(_8\)-cycloalkyl, -0-C\(_3\)-C\(_8\)-heterocyclyl, -0-C\(_5\)-Ci\(_0\)-aryl, -0-C\(_5\)-Cio-heteroaryl, -Co-C\(_6\)-alkylene-CN, -Co-C\(_4\)-alkylene-0-Ci-C\(_4\)-alkyl, -Co-C\(_4\)-alkylene-0-C\(_3\)-C\(_8\)-cycloalkyl, -Co-C\(_4\)-alkylene-0-C\(_5\)-C\(_8\)-heterocyclyl, -Co-C\(_4\)-alkylene-0-C\(_5\)-Cio-aryl, -Co-C\(_4\)-alkylene-0-C\(_5\)-Cio-heteroaryl, -Co-C\(_4\)-alkylene-Q-Co-C\(_4\)-alkyl-N(R\(_9\),R\(_9\)'), -Co-C\(_4\)-alkylene-N(Rio)-Q-Ci-C\(_4\)-alkyl, -Co-C\(_4\)-alkylene-N(Rio)-Q-C\(_3\)-C\(_8\)-cycloalkyl, -Co-C\(_4\)-alkylene-N(Rio)-Q-C\(_3\)-C\(_8\)-heterocyclyl, -Co-C\(_4\)-alkylene-N(Rio)-Q-C\(_5\)-Cio-aryl, -Co-C\(_4\)-alkylene-N(Rio)-Q-C\(_5\)-Cio-heteroaryl, -Co-C\(_4\)-alkylene-Q-N(Rn,Rir), -Co-C\(_4\)-alkylene-Q-N(Ri\(_2\))-Q-N(Ri\(_3\),Ri\(_3\)'), -Co-C\(_4\)-alkylene-Ri\(_4\), -Co-C\(_4\)-alkylene-Q-C-alkyl, -Co-C\(_4\)-alkylene-Q-C\(_3\)-C\(_8\)-cycloalkyl, -Co-C\(_4\)-alkylene-Q-C\(_3\)-C\(_8\)-heterocyclyl, -Co-C\(_4\)-alkylene-Q-C\(_5\)-Cio-aryl, -Co-C\(_4\)-alkylene-Q-C\(_5\)-Cio-heteroaryl, -Co-C\(_4\)-alkylene-0-Q-N(Ri\(_5\),Ri\(_5\)'), an d -Co-C\(_4\)-alkylene-N(Ri\(_6\))-Q-0-(Ri\(_7\)), wherein \( Q \) is selected from among -C(0)-, and -SO\(_2\)-,

wherein \( R_{i2}, R_{i6} \), are independently selected from among -H, -Ci-C\(_6\)-alkyl, and -C\(_3\)-C\(_6\)-cycloalkyl,

wherein \( R_9, R_9', Rio, Rn, Rir, Ri_3, Ri_3', R_{i5}, Ri_5' \), are independently selected from among -H, -Ci-C\(_6\)-alkyl, and -C\(_3\)-C\(_6\)-cycloalkyl,

or wherein \( R_9 \) and \( R_9' \), \( R_{i11} \) and \( R_{i11} \), \( Ri_3 \) and \( Ri_3' \), \( R_{i5} \) and \( R_{i5}' \) together form a -C\(_2\)-C\(_6\)-alkylene group,

wherein \( R_{14} \) and \( R_{17} \) are independently selected from among -H, -Ci-C\(_6\)-alkyl, -C\(_5\)-Cio-aryl, -C\(_5\)-Cio-heteroaryl, -C\(_3\)-Cs-cycloalkyl, and -C\(_3\)-C\(_8\)-heterocyclyl, wherein said -C\(_3\)-Cs-heterocyclyl optionally comprises nitrogen and/or -SO\(_2\)- in the ring,

and wherein \( R_{14} \) and \( R_{17} \) are optionally substituted with one or more groups selected from among -OH, -OCH\(_3\), -CF\(_3\), -OCF\(_3\), -CN, -halogen, -Ci-C\(_4\)-alkyl, =0, and -SO\(_2\)-Ci-C\(_4\)-alkyl, or wherein \( R_4 \) and/or \( R_5 \) are independently selected from among an electron pair, -H, and a group of the structure -L\(_2\)-Ri\(_8\), wherein \( L_2 \) is selected from among -NH- and -N(Ci-C\(_4\)-alkyl)-.
wherein \( R_i \) is selected from among \(-C_5-C_{10}-\text{aryl}, -Cs-C_{10}-\text{heteroaryl}, -C_3-C_8-\text{cycloalkyl}, \) and \(-C_3-Cs-\text{heterocyclyl}, \)

wherein \( R_i \) is optionally substituted by one or more groups selected from among halogen, \(-CF_3, -OCF_3, -CN, -OH, -0-Ci-C_4-\text{alkyl}, -Ci-C_6-\text{alkyl}, -NH-C_6-(0)-Ci-C_6-\text{alkyl}, -N(Ci-C_4-alkyl)-C(0)-Ci-C_6-\text{alkyl}, -C(0)-Ci-C_6-\text{alkyl}, -S(0)_2-Ci-C_6-\text{alkyl}, -N(Ci-C_4-alkyl)-S(0)_2-Ci-C_6-\text{alkyl}, \) and \(-C(0)-0-Ci-C_6-\text{alkyl}, \)

and wherein \( R_4, R_5 \) and \( R_i \) are optionally further substituted by spiro-\( C_3-Cs-\text{cycloalkyl} \) or spiro-\( C_3-C_8-\text{heterocyclyl} \) such that together with \( R_4, R_5 \) and/or \( R_i \) a spirocycle is formed, wherein said spiro-\( C_3-C_8-\text{heterocyclyl} \) optionally comprises one or more groups selected from among nitrogen, \(-C(O)-, -SO_2-, \) and \(-N(SO_2-Ci-C_4-\text{alkyl})-i\) in the ring,

or wherein \( R_4, R_5 \) and \( R_i \) are optionally further bi-valently substituted by one or more spirocyclic or annellated ring forming groups selected from among \(-Ci-C_6-\text{alkylene}, -C_2-C_6-\text{alkenylene}, \) and \(-C_4-C_6-\text{alkynylene}, \) in which one or two carbon centers may optionally be replaced by one or two hetero atoms selected from among \( N, O \) and \( S \) and which may optionally be substituted by one or more groups on one ring atom or on two neighbouring ring atoms selected from among \(-OH, -NH_2, -Ci-C_3-\text{alkyl}, 0-Ci-C_6-\text{alkyl}, -CN, -CF_3, -OCF_3, \) and halogen;

as well as in form of their acid addition salts with pharmacologically acceptable acids.

Preferred compounds of the invention are compounds according to formula (I)

\[
\begin{align*}
\text{A} & \quad \text{N} \\
\text{R}_2 & \quad \text{R}_3 \\
\text{R}_1 & \quad \text{R}_7 \\
\text{Z} & \quad \text{R}_4 \\
\text{R}_5 & \quad \text{R}_6
\end{align*}
\]

wherein \( A \) is a group selected from among \(-NH-LI-R_7, -NCH_3-Li-R_7, -0-Li-R_7, \) and the structure (II)

\[
\begin{align*}
\text{R}_6 & \\
\text{R}_5 & \quad \text{N-}\ast
\end{align*}
\]

wherein \( Li \) is a linker selected from a bond or a group selected from among \(-Ci-C_2-\text{alkylene}, \) and \(-Ci-C_2-\text{alkenylene} \) which optionally comprises one or more groups selected from \(-0-, -\).
C(O)-, and -NH- in the chain and which is optionally substituted by a group selected from among -OH, -NH$_2$, - Ci-C$_5$-alkyl, - Ci-C$_5$-alkyl, and -CN,
wherein R$_7$ is a ring selected from among - C$_3$-C$_8$- cycloalkyl, - C$_3$-Cs -heterocyclyl, - C$_5$-C10-aryl, and -C$_8$-Cs -heteroaryl,
wherein the ring R$_7$ is optionally substituted with one or more groups selected from among
- CF$_3$, - Ci-C$_5$-alkyl, -0-CF$_3$, - CN, - O-Ci-C$_5$- alkyl, - Ci-C$_6$- alkenyl, and - Ci-C$_5$ - alkylnyl, and - halogen,
or wherein the ring R$_7$ is optionally substituted with one or more groups selected from among
- C$_5$-Ci-C$_5$-aryl, - Cs-Cio - heteroaryl, - C$_3$-C$_8$- cycloalkyl, - C$_3$-Cs -heterocyclyl, optionally being
substituted by one or more groups selected from among -OH, - NH$_2$, - Ci-C$_4$ - alkyl, -0-Ci-C$_6$ - alkyl, - CN, - CF$_3$, - OCF$_3$, halogen, and =0,
or wherein the ring R$_7$ is optionally further bi-valently substituted on two neighbouring ring atoms, such that an annellated ring is formed by one or more groups selected from among - Ci-C$_6$- alkenylene, - C$_2$-C$_6$- alkenylene and - C4-C6- alkylnylene, in which one or two carbon centers
may optionally be replaced by 1 or 2 hetero atoms selected from N, O and S, the bivalent
group being optionally substituted by one or more groups selected from -OH, - NH$_2$, - Ci-C$_3$- alkyl, - O-Ci-C$_5$ - alkyl, - CN, - CF$_3$, - OCF$_3$, halogen, and =0;
wherein R$_6$ is selected from among - H, - halogen, - CN, - O-Ci-C$_4$- alkyl, - Ci-C$_4$ - alkyl,
- CH=CH$_2$, - C=CH, - CF$_3$, - OCF$_3$, - OCF$_2$ H, and - OCFH$_2$;
wherein R$_2$ is selected from among - H, - halogen, - CN, - O-Ci-C$_4$- alkyl, - Ci-C$_4$ - alkyl,
- CH=CH$_2$, - C=CH, - cyclopropyl, - CF$_3$, - OCF$_3$, - OCF$_2$ H, and - OCFH$_2$;
wherein R$_3$ is selected from among - H, - methyl, - ethyl, - propyl, - i-propyl, - cyclopropyl,
- OCH$_3$, - OH, and - CN;
wherein Z is C or N;
wherein R$_i$ is selected from among - H, - Ci-C$_4$- alkyl, - OH, -0-Ci-C$_4$- alkyl, - halogen, - CN,
- CF$_3$, and - OCF$_3$;
wherein n is 1, 2 or 3;
wherein R$_5$ is selected from among an electron pair, - H, and a group selected from among
- Ci-C$_6$ - alkyl, - NH$_2$, - C$_3$-C$_8$- cycloalkyl, - C$_3$-Cs -heterocyclyl, - C$_5$-Ci - aryl, - Cs-Cio - heteroaryl, and - C(0)-(N(R$_8$Rs')) with R$_8$ and Rs' independently being selected from among - H, and - Ci-
C$_6$- alkyl,
and wherein R$_5$ if different from an electron pair or - H are optionally independently
substituted with one or more groups selected from among - halogen, - OH, - CF$_3$, - CN, - Ci-C$_6$ - alkyl, -0-Ci-C$_6$- alkyl, -0-C$_3$-C$_8$- cycloalkyl, -0-C$_3$-C$_8$- heterocyclyl, -0-C$_5$-Ci$_0$- aryl,
-0-C$_5$-Ci$_0$- heteroaryl, - C$_0$-C$_6$- alkenylene-CN, - C$_0$-C$_4$- alkylene-O-Ci-C$_4$- alkyl,
- Co-C$_4$- alkylene-0-C$_3$-C$_8$- cycloalkyl, - Co-C$_4$- alkylene-0-C$_3$-C$_8$- heterocyclyl, - Co-C$_4$-alkylene-
0-C$_5$-Ci$_0$- aryl, - Co-C$_4$- alkylene-0-C$_5$-Ci$_0$- heteroaryl, - Co-C$_4$-alkylene-Q-Co-C$_4$- alkyl-
N(R$_9$R$_9'$), - Co-C$_4$-alkylene-N(Rio)-Q-Ci-C$_4$- alkyl,
- Co-C$_4$-alkylene-N(Rio)-Q-C$_3$-C$_8$- cycloalkyl, - Co-C$_4$-alkylene-N(Rio)-Q-C$_3$-C$_8$- heterocyclyl,

-Co-C₄-alkylene-Q-C₅-Cio-heteroaryl, -Co-C₄-alkylene-0-Q-N(Ri5,Ri5’), and

-Co-C₄-alkylene-N(Ri₆)-Q-O-(Ri₇).

wherein Q is selected from among -C(O)-, and -S₀₂⁻, wherein Ri₂ and Ri₆ are independently selected from among -H, -Ci-C₆-alkyl, and -C₃-C₆-cycloalkyl,

wherein R₉, R₉’, Ri, Rn, Rir, R₁₃, R₁₃’, R₁₅, Ri₅’ are independently selected from among -H, -Ci-C₆-alkyl, and -C₃-C₆-cycloalkyl, or wherein R₉ and R₉’, Ri and Rn, Rir, R₁₃ and R₁₃’, R₁₅ and R₁₅’ together form a -C₂⁻C₆⁻

alkylene group, wherein R₁₄ and R₁₇ are independently selected from among -H, -Ci-C₆-alkyl, -C₅⁻Cio-aryl, -C₂⁻C₆⁻Cio-heteroaryl, -C₃⁻C₆⁻cycloalkyl, and -C₄⁻C₆⁻heteroalkyl optionally comprises nitrogen and/or -S₀₂⁻ in the ring, and wherein R₁₄ and R₁₇ are optionally substituted with one or more groups selected from among -OH, -OCH₃, -CF₃, -OCF₃, -CN, -halogen, -Ci-C₄⁻alkyl, =O, and -S₀₂⁻Ci-C₄⁻alkyl, or wherein R₅ is selected from among an electron pair, -H, and a group of the structure -L₂⁻

R₁₈,

wherein L₂ is selected from among -NH- and -N(Ci-C₄⁻alkyl)-, wherein R₁₈ is selected from among -C₅⁻Cio-aryl, -Cs⁻Cio-heteroaryl, -C₃⁻C₆⁻cycloalkyl, and -C₃⁻C₆⁻heterocyclyl, wherein R₁₈ is optionally substituted by one or more groups selected from among halogen, -CF₃, -OCF₃, -CN, -OH, -0-Ci-C₄⁻alkyl, -Ci-C₆⁻alkyl, -NH-C(0)-Ci-C₆⁻alkyl, -N(Ci-C₄⁻alkyl)-C(0)-Ci-C₆⁻alkyl, -C(0)-Ci-C₆⁻alkyl, -S(0)⁻₂⁻Ci-C₆⁻alkyl, -NH-S(0)⁻₂⁻Ci-C₆⁻alkyl, -N(Ci-C₄⁻alkyl)-S(0)⁻₂⁻Ci-C₆⁻alkyl, and -C(0)-0-Ci-C₆⁻alkyl, and wherein R₄, R₅ and R₁₈ are optionally further substituted by spiro-C₃⁻C₆⁻cycloalkyl or spiro-C₃⁻C₆⁻heterocyclyl such that together with R₄, R₅ and/or R₁₈ a spirocycle is formed, wherein said spiro-C₃⁻C₆⁻heterocyclyl optionally comprises one or more groups selected from among nitrogen, -C(O)-, -S₀₂⁻, and -N(S₀₂⁻Ci-C₄⁻alkyl)- in the ring, or wherein R₅ and R₁₈ are optionally further bi-valently substituted by one or more spirocyclic or annellated ring forming groups selected from among -Ci-C₆⁻alkylene, -C₂⁻C₆⁻alkenylene, and -C₄⁻C₆⁻alkynylene, in which one or two carbon centers may optionally be replaced by one or two hetero atoms selected from among N, O and S and which may optionally be substituted by one or more groups on one ring atom or on two neighbouring ring atoms selected from among -OH, -NH₂, -Ci-C₃⁻alkyl, 0-Ci-C₆⁻alkyl, -CN, -CF₃, -OCF₃, and halogen;
wherein \( R_4 \) is selected from among -H, -C\(_3\)alkyl, -OH, -CF\(_3\), -OCF\(_3\), and halogen, more preferred from among -H, and -C\(_3\)-alkyl, most preferred wherein \( R_4 \) denotes -H; as well as in form of their acid addition salts with pharmacologically acceptable acids.

Preferred compounds of formula (I) according to the invention are compounds, wherein \( A \) is a group selected from among -NH-L\(_i\)-R\(_7\), -O-L\(_i\)-R\(_7\), and the structure (II)

![Diagram](II)

wherein \( L_i \) is a linker selected from a bond or a group selected from among -C\(_i\)-C\(_{2}\)-alkylene, wherein \( R_7 \) is a ring selected from among -C\(_3\)-C\(_8\)-cycloalkyl, -C\(_3\)-C\(_s\)-heterocyclyl, and -C\(_5\)-C\(_{10}\)-aryl, wherein the ring \( R_7 \) is optionally substituted with one or more groups selected from among -CF\(_3\), -C\(_i\)-C\(_6\)-alkyl, and -0-CF\(_3\), or wherein the ring \( R_7 \) is optionally substituted with one or more groups selected from among -C\(_5\)-C\(_{10}\)-aryl, optionally being substituted by one or more groups selected from among -C\(_i\)-C\(_{4}\)-alkyl, and -OCF\(_3\);

wherein \( R_6 \) denotes -CF\(_3\);

wherein \( R_2 \) is selected from among -H, -C\(_i\)-C\(_4\)-alkyl, and -CF\(_3\);

wherein \( R_3 \) is selected from among -H, -OCH\(_3\), and -OH;

wherein \( Z \) denotes C;

wherein \( R_i \) denotes -H;

wherein \( n \) is 2;

wherein \( R_4 \) denotes -H, and \( R_5 \) is a group selected from -C\(_3\)-C\(_s\)-heterocyclyl, and wherein \( R_5 \) is optionally substituted with one or more groups selected from among -Co-C\(_4\)-alkylene-N(R\(_{10}\))-Q-Ci-C\(_{4}\)-alkyl,

wherein \( Q \) is denotes -S\(_0\)-, and wherein \( R_{10} \), is selected from among -H, and -d-Ce-alkyl, or wherein \( R_4 \) denotes -H, and \( R_5 \) is selected from a group of the structure -L\(_2\)-R\(_{18}\), wherein \( L_2 \) denotes -NH- and wherein \( R_{18} \) is selected from among -d-d-heterocyclyl, wherein \( R_{18} \) is optionally substituted by one or more groups selected from among -0-Ci-C\(_{4}\)-alkyl.

Preferred compounds of formula (I) according to the invention are compounds, wherein \( A \) is a group selected from among -NH-L\(_i\)-R\(_7\), and the structure (II)

![Diagram](II)
wherein Li is a linker selected from a bond or a group selected from among -Ci-C₂-alkylene, wherein R₇ is a ring selected from among -C₃-C₈-cycloalkyl, -C₃-C₇-heterocyclyl, and -C₅-C₁₀-aryl, wherein the ring R₇ is optionally substituted with one or more groups selected from among -CF₃, -Ci-C₆-alkyl, and -O-CF₃,

or wherein the ring R₇ is optionally substituted with one or more groups selected from among -C₅-C₁₀-aryl, optionally being substituted by one or more groups selected from among -Ci-C₄-alkyl, and -O-CF₃;

wherein R₆ denotes -CF₃;

wherein R₂ is selected from among -H, -Ci-C₄-alkyl, and -CF₃;

wherein R₃ is selected from among -H, and -OCH₃;

wherein Z denotes C;

wherein Ri denotes -H;

wherein n is 2;

wherein R₄ denotes -H, and R₅ is a group selected from -C₃-C₅-heterocyclyl, and wherein R₅ is optionally substituted with one or more groups selected from among -C₀-C₄-alkylene-N(Rio)-Q-Ci-C₄-alkyl,

wherein Q is denotes -SO₂-, and wherein R₁₀ is selected from among -H, and -Ci-C₅-alkyl, or wherein R₄ denotes -H, and R₅ is selected from a group of the structure -L₂-Ris,

wherein L₂ denotes -NH- and wherein Ri₈ is selected from among -C₃-C₅-heterocyclyl, wherein Ri₈ is optionally substituted by one or more groups selected from among -O-CH₃.

Preferred compounds of formula (I) according to the invention are compounds with R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, R₂₀, R₂₀, R₂₁, R₂₁, L₂, Z, Q, and n as herein before or below defined,

wherein A is -NH-Li-R₇,

and wherein Li is a bond or wherein Li denotes methylene, and wherein R₇ is a ring selected from among -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, -cycloheptyl, -pyrrolidinyl, -piperidinyl, -azepanyl, -tetrahydrofuranyl, -tetrahydropyranyl, -oxepanyl, -phenyl, -pyridyl, and -furanyl, wherein the ring R₇ is optionally substituted with one or more groups selected from among -F, -Cl, -methyl, -ethyl, -propyl, -i-propyl, -cyclopropyl, -t-butyl, -CF₃, -O-CF₃, -CN, -O-methyl, -furanyl and -phenyl, wherein said phenyl is optionally independently substituted by one or more groups selected from among -Ci-C₄-alkyl, halogen, -OCH₃, -CF₃, and -O-CF₃.

Preferred compounds of formula (I) according to the invention are compounds with R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, R₂₀, R₂₀, R₂₁, R₂₁, L₂, Z, Q, and n as herein before or below defined,

wherein A is -NH-Li-R₇.
and wherein \( L_i \) is a bond or wherein \( L_i \) denotes methylene,
and wherein \( R_i \) is a ring selected from among \(-\text{cyclohexyl}, -\text{tetrahydropyranyl}, \) and \(-\text{phenyl}, \)
wherein the ring \( R_i \) is optionally substituted with one or more groups selected from among
\(-\text{t-butyl}, \) and \(-\text{phenyl}, \) wherein said \(-\text{phenyl} \) is optionally independently substituted by one or
more groups selected from among \(-\text{C}-\text{C}_4 \) -alkyl, \(-\text{CF}_3 \), and \(-\text{OCF}_3 \).

Preferred compounds of formula (I) according to the invention are compounds with \( R_2, R_3, \)
\( R_4, R_5, R_8, R_9, R_9^\prime, R_9^\prime, R_9^\prime, \) \( R_11, R_11, R_12, R_12, R_13, R_13^\prime, R_14, R_15, R_15^\prime, R_16, R_17, R_18, R_20, R_20^\prime, R_21, \)
\( R_2^\prime, L_2, Z, Q, \) \( \) and \( n \) as herein before or below defined,
wherein \( A \) is \(-\text{NH-Li-R}_7 \)
and wherein \( L_i \) is a bond or wherein \( L_i \) denotes methylene,
and wherein \( R_i \) is a ring selected from among \(-\text{C}_3-\text{C}_8 \) -heterocyclyl, and \(-\text{C}_5-\text{C}_10 \) -aryl,
wherein the ring \( R_i \) is optionally substituted with one or more groups selected from among
\(-0-\text{CF}_3, -\text{C}-\text{C}_6 \) -alkyl,
wherein \( A \) denotes a group selected from among formula (III)

\[
\text{(II)}
\]
wherein \( R_{19} \) denotes the ring \(-\text{C}_5-\text{C}_10 \) -aryl, preferably wherein \( R_{19} \) denotes \(-\text{phenyl}, \)
and wherein the ring \( R_{19} \) is optionally substituted with one or more groups selected from among
\(-0-\text{CF}_3, \) and \(-\text{C}-\text{C}_6 \) -alkyl, preferably by a group selected from among \(-0-\text{CF}_3 \).

Preferred compounds of formula (I) according to the invention are compounds with \( R_2, R_3, \)
\( R_4, R_5, R_8, R_9, R_9^\prime, R_9^\prime, R_9^\prime, \) \( R_11, R_11, R_12, R_12, R_13, R_13^\prime, R_14, R_15, R_15^\prime, R_16, R_17, R_18, R_20, R_20^\prime, R_21, \)
\( R_2^\prime, L_2, Z, Q, \) \( \) and \( n \) as herein before or below defined,
wherein \( A \) is a group selected from among formula (IV) and (V)

\[
\text{(IV), and (V),}
\]
wherein \( R_{19} \) is \(-\text{H}, -0-\text{CF}_3, \) and \(-\text{C}-\text{C}_6 \) -alkyl.
Preferred compounds of formula (I) according to the invention are compounds with $R_1$, $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_9'$, $R_{10}$, $R_{11}$, $R_{11}'$, $R_{12}$, $R_{13}$, $R_{13}'$, $R_{14}$, $R_{15}$, $R_{15}'$, $R_{16}$, $R_{17}$, $R_{18}$, $R_{19}$, $R_{20}$, $R_{20}'$, $R_{21}$, $R_{21}'$, $A$, $L_i$, $L_2$, $Z$, $Q$, and $n$ as herein before or below defined, wherein $R_2$ is selected from among -H, -CF$_3$, and -CH$_3$, preferably selected from -CH$_3$.

Preferred compounds of formula (I) according to the invention are compounds with $R_1$, $R_2$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_9'$, $R_{10}$, $R_{11}$, $R_{11}'$, $R_{12}$, $R_{13}$, $R_{13}'$, $R_{14}$, $R_{15}$, $R_{15}'$, $R_{16}$, $R_{17}$, $R_{18}$, $R_{19}$, $R_{20}$, $R_{20}'$, $R_{21}$, $R_{21}'$, $A$, $L_i$, $L_2$, $Z$, $Q$, and $n$ as herein before or below defined, wherein $R_3$ is selected from among -H, -OCH$_3$, and methyl, preferably selected from -OCH$_3$.

Preferred compounds of formula (I) according to the invention are compounds with $R_2$, $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_9'$, $R_{10}$, $R_{11}$, $R_{11}'$, $R_{12}$, $R_{13}$, $R_{13}'$, $R_{14}$, $R_{15}$, $R_{15}'$, $R_{16}$, $R_{17}$, $R_{18}$, $R_{19}$, $R_{20}$, $R_{20}'$, $R_{21}$, $R_{21}'$, $A$, $L_i$, $L_2$, $Z$, $Q$, and $n$ as herein before or below defined, wherein $R_i$ is selected from among -H, and -CH$_3$, preferably wherein $R_i$ denotes -H.

Preferred compounds of formula (I) according to the invention are compounds with $R_1$, $R_2$, $R_3$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_9'$, $R_{10}$, $R_{11}$, $R_{11}'$, $R_{12}$, $R_{13}$, $R_{13}'$, $R_{14}$, $R_{15}$, $R_{15}'$, $R_{16}$, $R_{17}$, $R_{18}$, $R_{19}$, $R_{20}$, $R_{20}'$, $R_{21}$, $R_{21}'$, $A$, $L_i$, $L_2$, $Z$, $Q$, and $n$ as herein before or below defined, wherein $R_4$ denotes -H.

Preferred compounds of formula (I) according to the invention are compounds with $R_1$, $R_2$, $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_9'$, $R_{10}$, $R_{11}$, $R_{11}'$, $R_{12}$, $R_{13}$, $R_{13}'$, $R_{14}$, $R_{15}$, $R_{15}'$, $R_{16}$, $R_{17}$, $R_{18}$, $R_{19}$, $R_{20}$, $R_{20}'$, $R_{21}$, $R_{21}'$, $A$, $L_i$, $L_2$, $Z$, and $Q$, as herein before or below defined, wherein $n$ is 2.

Preferred compounds of formula (I) according to the invention are compounds with $R_1$, $R_2$, $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_9'$, $R_{10}$, $R_{11}$, $R_{11}'$, $R_{12}$, $R_{13}$, $R_{13}'$, $R_{14}$, $R_{15}$, $R_{15}'$, $R_{16}$, $R_{17}$, $R_{18}$, $R_{19}$, $R_{20}$, $R_{20}'$, $R_{21}$, $R_{21}'$, $A$, $L_i$, $L_2$, $Z$, $Q$, and $n$ as herein before or below defined, wherein $Z$ denotes C.

Preferred compounds of formula (I) according to the invention are compounds with $R_1$, $R_2$, $R_3$, $R_6$, $R_7$, $R_{19}$, $A$, $L_i$, $Q$, and $n$ as herein before or below defined, wherein $Z$ denotes C, and wherein $R_4$ denotes -H, and wherein $R_5$ denotes a group of the structure -L$_2$-Ri8, wherein L$_2$ is a group selected from among -NH-, and -N(CH$_3$)$_2$-, wherein Ri8 is -C$_6$-heterocycl comprising 1 hetero atom selected from O, wherein Ri8 is optionally substituted by -O-CH$_3$.
or wherein \( R^4 \) denotes -H and \( R^2 \) denotes a group of the structure -N(R_2o,R_2o'),
wherein \( R_{2o} \) and \( R_{2o'} \) together form a -C_4-C_5-alkylene group such that a ring is formed,
wherein such ring is optionally substituted with one or more groups selected from among -OH, and -N(C_0-Ci-alkyl)-SO_2-CH_3;

or wherein \( R^4 \) denotes -H, and wherein \( R^3 \) denotes a group of the structure -N(R_{2i},R_{2r}),
wherein \( R_{2i} \) and \( R_{2r} \) together form a -C_5-alkylene group such that a ring is formed, in which one carbon center of the -C_5-alkylene group is replaced by one hetero atom selected from O.

Preferred compounds of formula (I) according to the invention are compounds with \( R_1, R_2, \)
\( R_3, R_6, R_7, R_{i9}, A, Li, Q, \) and \( n \) as herein before or below defined,

wherein

\( Z \) denotes C, and

wherein \( R^4 \) denotes -H, and wherein \( R^5 \) denotes a group of the structure -L_2-R_{i8},
wherein \( L_2 \) is a group selected from among -NH- , and -N(CH_3)-,

or wherein \( R_{i8} \) is -C_6-heterocyclyl comprising 1 hetero atom selected from O,
wherein \( R_{i8} \) is optionally substituted by a group selected from among -F, and -0-CH_3;

or wherein \( R^4 \) denotes -H and \( R^5 \) denotes a group of the structure -N(R_{2o},R_{2o'}),
wherein \( R_{2o} \) and \( R_{2o'} \) together form a -C_4-C_5-alkylene group such that a ring is formed,
wherein such ring is optionally substituted with one or more groups selected from among -OH, and -N(C_0-Ci-alkyl)-SO_2-CH_3;

Preferred compounds of formula (I) according to the invention are compounds with \( R_1, R_2, \)
\( R_3, R_6, R_7, R_{i9}, A, Li, Q, \) and \( n \) as herein before or below defined,
wherein
Z denotes C, and
wherein R denotes -H, and wherein R denotes a group of the structure -L₂-R₁,
wherein L₂ is a group selected from among -NH-, wherein R₁ is -C₆-heterocycl comprising 1 hetero atom selected from O,
wherein R₁ is optionally substituted by -O-CH₃;
or wherein R denotes -H and R₂ denotes a group of the structure -N(R₂₀,R₂₀'),
wherein R₂₀ and R₂₀' together form a -C₄-Cs-alkylene group such that a ring is formed,
wherein such ring is optionally substituted with one or more groups selected from among -OH, and -N(C₀-Ci-alkyl)-SO₂-CH₃.

Preferred compounds of formula (I) according to the invention are compounds with R₁, R₂, R₃, R, R₇, R₉, A, Li, Q, and n as herein before or below defined,
wherein
Z denotes C, and
wherein R denotes -H, and wherein R denotes a group of the structure -L₂-R₁,
wherein L₂ is a group selected from among -NH-, wherein R₁ is -C₆-heterocycl comprising 1 hetero atom selected from O,
wherein R₁ is optionally substituted by -F;
or wherein R denotes -H and R₂ denotes a group of the structure -N(R₂₀,R₂₀'),
wherein R₂₀ and R₂₀' together form a -C₄-Cs-alkylene group such that a ring is formed,
wherein such ring is optionally substituted with one or more groups selected from among -OH, and -N(C₀-Ci-alkyl)-SO₂-CH₃.

Preferred compounds of formula (I) according to the invention are compounds with R₁, R₂, R₃, R₆, R₇, R₉, A, Li, Q, and n as herein before or below defined,
wherein
Z denotes C, and
wherein R denotes -H, and wherein R denotes a group of the structure -L₂,R₁,
wherein L₂ is a group selected from among -NH-, wherein R₁ is -C₆-heterocycl comprising 1 hetero atom selected from O,
wherein R₁ is optionally substituted by -O-CH₃.

Preferred compounds of formula (I) according to the invention are compounds with R₁, R₂, R₃, R₆, R₇, R₉, A, Li, Q, and n as herein before or below defined,
wherein
Z denotes C, and
wherein R denotes -H, and wherein R denotes a group of the structure -L₂-R₁,
wherein L₂ is a group selected from among -NH-,
wherein \( R_{18} \) is \(-C_6\)-heterocycly comprising 1 hetero atom selected from O, wherein \( R_{18} \) is optionally substituted by -F.

All of the above embodiments under formula (I) have to be understood to optionally be present in form of their individual optical isomers, mixtures of their individual optical isomers, or racemates, as well as in form of their acid addition salts with pharmacologically acceptable acids, as well as in form of their solvates and/or hydrates.

It has now been found that such compounds as herein before or below defined could be used as a medicament.

It has been found that such compounds as herein before or below defined could be used for making a medicament for the treatment of inflammatory diseases. It has been found that such compounds as herein before or below defined could be used for making a medicament for the treatment of inflammatory diseases, wherein the inflammatory diseases are selected from inflammatory diseases of the respiratory tract. It has been found that such compounds as herein before or below defined could be used for making a medicament for the treatment of inflammatory diseases, wherein the inflammatory diseases are selected from chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It has been found that such compounds as herein before or below defined could be used for making a medicament for the treatment of neurologic diseases, preferably for the treatment of pain diseases especially for the treatment of inflammatory and neuropathic pain disease, especially for the treatment of chronic pain. It has been found that such compounds as herein before or below defined could be used for making a medicament for the treatment of immune related diseases, preferably for the treatment of diabetes mellitus. It has been found that such compounds as herein before or below defined could be used for making a medicament for the treatment of cardiovascular diseases, preferably for the treatment of peripheral atherosclerotic disease. It has been found that such compounds as herein before or below defined could be used for making a medicament for the treatment of diabetic nephropathy.

Present invention encloses compounds as herein before or below defined as medicaments.

Present invention encloses compounds as herein before or below defined as medicaments for the treatment of inflammatory diseases. Present invention encloses compounds as herein before or below defined as medicaments for the treatment of inflammatory diseases, wherein the inflammatory diseases are selected from inflammatory diseases of the respiratory tract. Present invention encloses compounds as herein before or below defined as medicaments for the treatment of inflammatory diseases, wherein the inflammatory diseases are selected from chronic obstructive pulmonary disease, asthma, and cystic fibrosis. Present invention encloses compounds as herein before or below defined as medicaments for the treatment of neurologic diseases, preferably for the treatment of pain diseases especially for the treatment of inflammatory and neuropathic pain disease, especially for the treatment of chronic pain.
Present invention encloses compounds as herein before or below defined as medicaments for the treatment of immune related diseases, preferably for the treatment of diabetes mellitus. Present invention encloses compounds as herein before or below defined as medicaments for the treatment of cardiovascular diseases, preferably for the treatment of peripheral atherosclerotic disease. Present invention encloses compounds as herein before or below defined as medicaments for the treatment of diabetic nephropathy. It has been found that such compounds as herein before or below defined could be used for the treatment of inflammatory diseases. It has been found that such compounds as herein before or below defined could be used for the treatment of inflammatory diseases, wherein the inflammatory diseases are selected from inflammatory diseases of the respiratory tract. It has been found that such compounds as herein before or below defined could be used for the treatment of inflammatory diseases, wherein the inflammatory diseases are selected from chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It has been found that such compounds as herein before or below defined could be used for the treatment of neurologic diseases, preferably for the treatment of pain diseases especially for the treatment of inflammatory and neuropathic pain disease, especially for the treatment of chronic pain. It has been found that such compounds as herein before or below defined could be used for the treatment of immune related diseases, preferably for the treatment of diabetes mellitus. It has been found that such compounds as herein before or below defined could be used for the treatment of cardiovascular diseases, preferably for the treatment of peripheral atherosclerotic disease. It has been found that such compounds as herein before or below defined could be used for the treatment of diabetic nephropathy.

Definitions

Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.

In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, -Ci-C6-alkyl means an alkyl group or radical having 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the last named subgroup is the radical attachment point, for example, the substituent "aryl-Ci-C3-alkyl-" means an aryl group which is bound to a Ci-C5-alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.

In case a compound of the present invention is depicted in form of a chemical name and as a formula in case of any discrepancy the formula shall prevail. An asterisk is may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
For example, the term "3-carboxypropyl-group" represents the following substituent:

![Structure](image)

wherein the carboxy group is attached to the third carbon atom of the propyl group. The terms "1-methylpropyl-", "2,2-dimethylpropyl-" or "cyclopropylmethyl-" group represent the following groups:

![Structures](image)

The asterisk may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined. Many of the following terms may be used repeatedly in the definition of a formula or group and in each case have one of the meanings given above, independently of one another.

Unless otherwise stated, all the substituents are independent of one another. If for example there might be a plurality of Ci-C<sub>6</sub>-alkyl groups as substituents in one group, in the case of three substituents Ci-C<sub>6</sub>-alkyl, one may represent methyl, one n-propyl and one tert-butyl.

Within the scope of this application, in the definition of possible substituents, these may also be represented in the form of a structural formula. An asterisk (*) in the structural formula of the substituent is to be understood as being the linking point to the rest of the molecule. Moreover, the atom of the substituent which follows the linking point is referred to as the atom in position number 1. Thus, for example, the groups N-piperidinyl (Piperidin-A), 4-piperidinyl (Piperidin-B), 2-tolyl (Tolyl-C), 3-tolyl (Tolyl-D), and 4-tolyl (Tolyl-E) are shown as follows:

![Structures](image)

If there is no asterisk (*) in the structural formula of the substituent, each hydrogen atom may be removed from the substituent and the valency thus freed may act as a binding site to the rest of a molecule. Thus, for example, (Tolyl-F) may represent 2-tolyl, 3-tolyl, 4-tolyl, and benzyl
The term "substituted" as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound.

By the term "optionally substituted" is meant within the scope of the invention the above-mentioned group, optionally substituted by a lower-molecular group. Examples of lower-molecular groups regarded as chemically meaningful are groups consisting of 1-200 atoms. Preferably such groups have no negative effect on the pharmacological efficacy of the compounds. For example the groups may comprise:

- Straight-chain or branched carbon chains, optionally interrupted by heteroatoms, optionally substituted by rings, heteroatoms or other common functional groups.
- Aromatic or non-aromatic ring systems consisting of carbon atoms and optionally heteroatoms, which may in turn be substituted by functional groups.
- A number of aromatic or non-aromatic ring systems consisting of carbon atoms and optionally heteroatoms which may be linked by one or more carbon chains, optionally interrupted by heteroatoms, optionally substituted by heteroatoms or other common functional groups.

By the term "branched or unbranched, saturated or unsaturated Ci-C\textsubscript{6}-carbon chain" it is meant a chain of carbon atoms, which is constituted by 1 to 6 carbon atoms arranged in a row and which can optionally further comprise branches or one or more hetero atoms selected from N, O or S. Said carbon chain can be saturated or unsaturated by comprising double or triple bonds.

If the carbon chain is to be substituted by a group which together with one or two carbon atoms of an alkylene chain forms a carbocyclic ring with 3, 5 or 6 carbon atoms, this includes the following examples of the rings:

![Example structures](image)

The term "Ci-C\textsubscript{n}-alkyl", wherein n is an integer from 2 to n, either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to n C atoms. For example the term Ci-Cs-alkyl embraces the radicals H\textsubscript{3}C-, H\textsubscript{3}C-CH\textsubscript{2}-, H\textsubscript{3}C-CH\textsubscript{2}-CH\textsubscript{2}-, H\textsubscript{3}C-CH\textsubscript{2}-CH\textsubscript{2}-CH\textsubscript{2}-, H\textsubscript{3}C-CH\textsubscript{2}-CH(CH\textsubscript{3})-, H\textsubscript{3}C-CH\textsubscript{2}-CH(CH\textsubscript{3})-CH\textsubscript{2}-, H\textsubscript{3}C-CH\textsubscript{2}-CH(CH\textsubscript{3})-CH\textsubscript{2}-CH\textsubscript{2}-, H\textsubscript{3}C-CH\textsubscript{2}-CH(CH\textsubscript{3})-CH\textsubscript{2}-CH\textsubscript{2}-CH\textsubscript{2}-,
H₃C-CH(CH₃)-CH₂-, H₃C-C(CH₃)₂-, H₃C-CH₂-CH₂-CH₂-CH₂-, H₃C-CH₂-CH₂-CH(CH₃)-, H₃C-CH₂-CH₂-CH(CH₃)-, H₃C-CH₂-CH₂-CH₂-CH₂-, H₃C-CH₂-CH₂-CH₂-CH₂-, H₃C-CH₂-C(CH₃)₂-, H₃C-C(CH₃)₂-, H₃C-CH₂(CH₃)-CH(CH₃)- and H₃C-CH₂-CH(CH₂CH₃). By the term "Ci-C₆-alkyl" (including those which are part of other groups) are meant branched and unbranched alkyl groups with 1 to 6 carbon atoms and by the term "Ci-C₄-alkyl" are meant branched and unbranched alkyl groups with 1 to 4 carbon atoms. Alkyl groups with 1 to 4 carbon atoms are preferred. By the term "Ci-C₃-alkyl" are meant branched and unbranched alkyl groups with 1 to 3 carbon atoms and by the term "C₂-C₄-alkyl" are meant branched and unbranched alkyl groups with 2 to 4 carbon atoms.

Examples for alkyl groups with 1-6 carbon atoms include: methyl, ethyl, n-propyl, β-o-propyl, n-butyl, α,β-o-butyl, sec-butyl, tert-butyl, n-pentyl, β,β-o-pentyl, neo-pentyl or hexyl. Optionally the abbreviations Me, Et, n-Pr, β-Pr, n-Bu, β-Bu, t-Bu, etc. may also be used for the above-mentioned groups. Unless stated otherwise, the definitions propyl, butyl, pentyl and hexyl include all the possible isomeric forms of the groups in question. Thus, for example, propyl includes n-propyl and β-o-propyl, butyl includes α-o-butyl, see-butyl and tert-butyl etc.

The term "Ci-C₉-alkylene" wherein n is an integer 2 to n, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 1 to n carbon atoms. For example the term Ci-C₄-alkylene includes -CH₂-, -CH₂-CH₂-, CH(CH₃)₂-, -CH₂-CH₂-CH₂-, -C(CH₃)₂-, -CH(CH₂CH₃)₂-, -CH(CH₃)-CH₂-, -CH₂-CH(CH₃)-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH(CH₃)-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂- and -C(CH₃)(CH₂CH₃). By the term "Ci-Cs-alkylene" (including those which are part of other groups) are meant branched and unbranched alkylene groups with 1 to 8 carbon atoms. By the term "C₂-C₈-alkylene" are meant branched and unbranched alkylene groups with 2 to 8 carbon atoms. By the term "C₄-C₆-alkylene" are meant branched and unbranched alkylene groups with 2 to 6 carbon atoms. By the term "Ci-C₄-alkylene" are meant branched and unbranched alkylene groups with 1 to 4 carbon atoms. By the term "Ci-C₂-alkylene" are meant branched and unbranched alkylene groups with 1 to 2 carbon atoms. By the term "Co-C₄-alkylene" are meant branched and unbranched alkylene groups with 0 to 4 carbon atoms, thus also a single bond is encompassed. By the term "Ci-C₃-alkylene" are meant branched and unbranched alkylene groups with 1 to 3 carbon atoms. Examples for Ci-Cs-alkylene include: methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene, pentylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene, hexylene, heptylene or octylene. Unless stated otherwise, the definitions propylene, butylene, pentylene, hexylene, heptylene and octylene include all the possible isomeric forms of the groups in question with the same
number of carbons. Thus, for example, propyl also includes 1-methylethylene and butylene includes 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene.

A -Ci-alkylene group, which is linked to a structure on two neighbouring ring atoms such that an annellated ring is formed, results to a C3-carbocycle. A -C2-alkylene group, which is linked to a structure on two neighbouring ring atoms such that an annellated ring is formed, results to a C4-carbocycle. A -C3-alkylene group, which is linked to a structure on two neighbouring ring atoms such that an annellated ring is formed, results to a C5-carbocycle. A -C4-alkylene group, which is linked to a structure on two neighbouring ring atoms such that an annellated ring is formed, results to a C6-carbocycle. A -C5-alkylene group, which is linked to a structure on two neighbouring ring atoms such that an annellated ring is formed, results to a Cycarbocycle. A -C6-alkylene group, which is linked to a structure on two neighbouring ring atoms such that an annellated ring is formed, results to a Cs-carbocycle.

In the definition of possible substituents, which are linked to such Ci-C6_alkylene groups forming a C3-Cs-carbocycle, it is to be understood that any of the atoms of the resulting C3-Cs-carbocycles could be the linking point for such a substituent.

If the carbon chain is to be substituted by a group which together with one or two carbon atoms of the alkylene chain forms a carbocyclic ring with 3, 5 or 6 carbon atoms, this includes the following examples of the rings:

![Structural diagrams](image)

The term "C2-Cn-alkenyl", is used for a group as defined in the definition for "Ci-Cn-alkyl" with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.

By the term "C2-C6-alkenyl" (including those which are part of other groups) are meant branched and unbranched alkenyl groups with 2 to 6 carbon atoms and by the term "C2-C4-alkenyl" are meant branched and unbranched alkenyl groups with 2 to 4 carbon atoms, provided that they have at least one double bond. Alkenyl groups with 2 to 4 carbon atoms are preferred. Examples for C2-C6-alkenyls include: ethenyl or vinyl, propenyl, butenyl, pentenyl, or hexenyl. Unless stated otherwise, the definitions propenyl, butenyl, pentenyl and hexenyl include all the possible isomeric forms of the groups in question. Thus, for example, propenyl includes 1-propenyl and 2-propenyl, butenyl includes 1-, 2- and 3-butenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl etc.

By the term "methylenylene" is meant a group with 1 carbon atom, provided that it is linked by a single bond as well as on the other side by a double bond. The asterisks (*) in the structural
The term "C$_2$-C$_n$-alkylene" is used for a group as defined in the definition for "Ci-C$_n$-alkylene" with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.

By the term "C$_2$-C$_8$-alkylene" (including those which are part of other groups) are meant branched and unbranched alkenylene groups with 2 to 8 carbon atoms and by the term "C$_2$-C$_6$-alkylene" are meant branched and unbranched alkenylene groups with 2 to 6 carbon atoms. By the term "Ci-C$_2$-alkylene" are meant alkenylene groups with 1 to 2 carbon atoms, provided that they have at least one double bond, whereas by the term "Ci-alkylene" is meant "methylenylene". Examples for C$_2$-Cs-alkenylenes include: ethylene, propylene, 1-methylethenylene, butylene, 1-methylpropylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene, pentenylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene, hexenylene, heptenylene or octenylene. Unless stated otherwise, the definitions propylene, butylene, pentenylene and hexenylene include all the possible isomeric forms of the groups in question with the same number of carbons. Thus, for example, propenyl also includes 1-methylethenylene and butenylene includes 1-methylpropylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene.

A - C$_3$-alkenylene group, which is linked to a structure on two neighbouring ring atoms such that an annellated ring is formed, results to a C$_5$-carbocycle. A - C$_4$-alkenylene group, which is linked to a structure on two neighbouring ring atoms such that an annellated ring is formed, results to a C$_6$-carbocycle. A - C$_5$-alkenylene group, which is linked to a structure on two neighbouring ring atoms such that an annellated ring is formed, results to a C$_7$-carbocycle. A - C$_6$-alkenylene group, which is linked to a structure on two neighbouring ring atoms such that an annellated ring is formed, results to a Cs-carbocycle.

In the definition of possible substituents, which are linked to such C$_3$-C$_6$-alkenylenes groups forming a Cs-Cs-carbocycle, it is to be understood that any of the atoms of the resulting Cs-Cs-carbocycles could be the linking point for such a substituent.

The term "C$_2$-C$_n$-alkynyl", is used for a group as defined in the definition for "Ci-C$_n$-alkyl" with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond.
By the term "C₂-C₆-alkynyl" (including those which are part of other groups) are meant branched and unbranched alkynyl groups with 2 to 6 carbon atoms and by the term "C₂-C₄-alkynyl" are meant branched and unbranched alkynyl groups with 2 to 4 carbon atoms, provided that they have at least one triple bond. Examples for C₂-C₆-alkynyls include: ethynyl, propynyl, butynyl, pentynyl or hexynyl. Unless stated otherwise, the definitions propynyl, butynyl, pentynyl and hexynyl include all the possible isomeric forms of the groups in question. Thus for example propynyl includes 1-propynyl and 2-propynyl, butynyl includes 1-, 2- and 3-butynyl, 1-methyl-1-propynyl, 1-methyl-2-propynyl etc.

The term "C₂-C₈-alkynylene" is used for a group as defined in the definition for "C₁-C₈-alkylene" with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond. By the term "C₂-C₈-alkynylene" (including those which are part of other groups) are meant branched and unbranched alkynylene groups with 2 to 8 carbon atoms and by the term "C₂-C₆-alkynylene" are meant branched and unbranched alkynylene groups with 2 to 6 carbon atoms. Examples of C₂-C₈-alkynlenes include: ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene, hexynylene, heptynylene or octynylene. Unless stated otherwise, the definitions propynylene, butynylene, pentynylene and hexynylene include all the possible isomeric forms of the groups in question with the same number of carbons. Thus for example propynyl also includes 1-methylethynylene and butynylene includes 1-methylpropynylene, 1, 1-dimethylethynylene, 1, 2-dimethylethynylene.

The term "carbocycl" as used either alone or in combination with another radical, means a mono- bi- or tricyclic ring structure consisting of 3 to 14 carbon atoms. The term "carbocycle" refers to fully saturated and aromatic ring systems and partially saturated ring systems. The term "carbocycle" encompasses fused, bridged and spirocyclic systems:
By the term "ring" are meant carbocycles, which can be saturated, unsaturated or aromatic and which optionally can comprise one or more hetero atoms selected from N, O or S.

The term "heterocycl" means a saturated or unsaturated mono- or polycyclic-ring systems including aromatic ring system containing one or more heteroatoms selected from N, O or S(0), wherein r = 0, 1 or 2, consisting of 3 to 14 ring atoms wherein none of the heteroatoms is part of the aromatic ring. The term "heterocycle" is intended to include all the possible isomeric forms.

Thus, the term "heterocycl" includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
By the term "-Cs-Cs-heterocyclyl" are meant three-, four-, five-, six-, seven-, or eight-membered, saturated or unsaturated heterocyclic rings which may contain one, two, or three heteroatoms, selected from among oxygen, sulfur, and nitrogen, whereas carbon atoms be replaced by such heteroatoms. The ring may be linked to the molecule through a carbon atom or through a nitrogen atom, if there is one. By the term "-Cs-Cs-heterocyclyl" are meant five-, six-, seven-, or eight-membered, saturated or unsaturated heterocyclic rings which may
contain one, two, or three heteroatoms, selected from among oxygen, sulfur, and nitrogen, while the ring may be linked to the molecule through a carbon atom or through a nitrogen atom, if there is one.

Examples for Cs-heterocycl include:

Examples for C₆-heterocycl include:

Examples for Cy-heterocycl include:

Unless otherwise mentioned, a heterocyclic ring (or "heterocycle") may be provided with a keto group. Examples include:

The term "C₃-C₆-cycloalkyl", wherein n is an integer from 3 to n, either alone or in combination with another radical denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to n C atoms. For example the term C₃-C₇-cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

By the term "Cs-Cs-cycloalkyl" (including those which are part of other groups) are meant cyclic alkyl groups with 3 to 8 carbon atoms. Likewise, by the term "C₃-C₆-cycloalkyl" are meant cyclic alkyl groups with 3 to 6 carbon atoms. Examples of Cs-Cs-cycloalkyls include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. Unless otherwise stated, the cyclic alkyl groups may be substituted by one or more groups selected from among methyl, ethyl, isopropyl, tert-butyl, hydroxy, fluorine, chlorine, bromine, and iodine.
The term "\(\text{C}_3\)-\(\text{C}_n\)-cycloalkenyl", wherein \(n\) is an integer from 3 to \(n\), either alone or in combination with another radical, denotes an cyclic, unsaturated but nonaromatic, unbranched hydrocarbon radical with 3 to \(n\) \(\text{C}\) atoms, at least two of which are bonded to each other by a double bond. For example the term \(\text{C}_3\cdot\text{C}_7\)-cycloalkenyl includes cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl and cycloheptatrienyl.

By the term "aryl" (including those which are part of other groups) are meant aromatic ring systems. By the term "\(\text{Cs-Cl}_6\)-aryl" (including those which are part of other groups) are meant aromatic ring systems with 5 to 10 carbon atoms. Preferred are "\(\text{Cs-Cl}_6\)-aryl" groups whereas aromatic rings are meant with 6 to 10 carbon atoms. Examples include: phenyl or naphthyl. Also preferred are "\(\text{Cs-Cl}_6\)-aryl" groups whereas aromatic rings are meant with 5 to 6 carbon atoms. Unless otherwise stated, the aromatic ring systems may be substituted by one or more groups selected from among methyl, ethyl, \(\text{iso-}\)propyl, \(\text{tert-}\)butyl, hydroxy, fluorine, chlorine, bromine and iodine.

The term "heteroaryl" means a mono- or polycyclic-ring systems containing one or more heteroatoms selected from \(\text{N}, \text{O}\) or \(\text{S}(0)\), wherein \(r = 0, 1\) or 2, consisting of 5 to 14 ring atoms wherein at least one of the heteroatoms is part of aromatic ring. The term "heteroaryl" is intended to include all the possible isomeric forms.

Thus, the term "heteroaryl" includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
By the term "Cs-Clo-heteroaryl" (including those which are part of other groups) are meant five- or six-membered heterocyclic aromatic groups or 5-10-membered, bicyclic heteroaryl rings which may contain one, two, or three heteroatoms selected from among oxygen, sulfur, and nitrogen, and contain so many conjugated double bonds that an aromatic system is formed. The following are examples of five- or six- or nine-membered heterocyclic aromatic groups:

Preferred are "Cs-Clc-heteroaryl" groups whereas aromatic rings are meant five- or six-membered heterocyclic aromatic groups. Unless otherwise stated, these heteroaryls may be substituted by one or more groups selected from among methyl, ethyl, isopropyl, tert-butyl, hydroxy, fluorine, chlorine, bromine, and iodine.
When a generic combined groups are used, for example -X-C\textsubscript{4}-alkyl- with X being a functional group such as -CO-, -NH-, -C(OH)- and the like, the functional group X can be located at either of the ends of the -Ci-C\textsubscript{4}-alkyl chain.

By the term "spiro-Cs-Cs-cycloalkyl" (spiro) are meant 3-8 membered, spirocyclic rings while the ring is linked to the molecule through a carbon atom. By the term "spiro-C3-C8-heterocyclyl" (spiro) are meant 3-8 membered, spirocyclic rings which may contain one, two, or three heteroatoms selected from among oxygen, sulfur, and nitrogen, while the ring may be linked to the molecule through a carbon atom or through a nitrogen atom, if there is one.

Unless otherwise mentioned, a spirocyclic ring may be provided with an oxo, methyl, or ethyl group. Examples include:

"Halogen" within the scope of the present invention denotes fluorine, chlorine, bromine or iodine. Unless stated to the contrary, fluorine, chlorine and bromine are regarded as preferred halogens.

"Linker" within the scope of the present invention denominates a bivalent group or a bond.

The above listed groups and residues can be combined to form more complex structures composed from carbon chains and rings or the like.

Compounds of general formula (I) may have acid groups, chiefly carboxyl groups, and/or basic groups such as e.g. amino functions. Compounds of general formula (I) may therefore occur as internal salts, as salts with pharmaceutically useable inorganic acids such as hydrochloric acid, sulphuric acid, phosphoric acid, sulphonic acid or organic acids (such as for example maleic acid, fumaric acid, citric acid, tartaric acid or acetic acid) or as salts with pharmaceutically useable bases such as alkali or alkaline earth metal hydroxides or carbonates, zinc or ammonium hydroxides or organic amines such as e.g. diethylamine, triethylamine, triethanolamine \textit{inter alia}.

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. For example, such salts include salts from ammonia, L-
arginine, betaine, benethamine, benzathine, calcium hydroxide, choline, deanol, 
diethanolamine (2,2’-iminobis(ethanol)), diethylamine, 2-(diethylamino)-ethanol, 2-
aminoethanol, ethylenediamine, N-ethyl-glucamine, hydralamine, IH-imidazole, lysine, 
magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1-
(2-hydroxyethyl)-pyrrolidine, sodium hydroxide, triethanolamine (2,2’;2”-nitrilotris(ethanol)), 
tromethamine, zinc hydroxide, acetic acid, 2,2-dichloro-acetic acid, adipic acid, alginate, 
ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 2,5-dihydroxybenzoic acid, 
4-acetamido-benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, carbonic acid, 
cinnamic acid, citric acid, cyclamic acid, decanoic acid, dodecysulfuric acid, ethane-1,2-
disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, 
ethylenediaminetetraacetic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, D-
glucoheptonic acid, D-gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, 2-oxo-
glutaric acid, glycerophosphoric acid, glycine, glycolic acid, hexanoic acid, hippuric acid, 
hydrobromic acid, hydrochloric acid, isobutyric acid, DL-lactic acid, lactobionic acid, lauric 
acid, lysine, maleic acid, (-)-L-malic acid, malonic acid, DL-mandelic acid, methanesulfonic 
acid, galactaric acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-
2-naphthoic acid, nicotinic acid, nitric acid, octanoic acid, oleic acid, orotic acid, oxalic acid, 
palmitic acid, pamoic acid (embonic acid), phosphoric acid, propionic acid, (-)-L-
pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic 
acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid and 
undecylenic acid. Further pharmaceutically acceptable salts can be formed with cations from 
metals like aluminium, calcium, lithium, magnesium, potassium, sodium, zinc and the like, 
The pharmaceutically acceptable salts of the present invention can be synthesized from the 
parent compound which contains a basic or acidic moiety by conventional chemical methods. 
Generally, such salts can be prepared by reacting the free acid or base forms of these 
compounds with a sufficient amount of the appropriate base or acid in water or in an organic 
diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof. 

As mentioned hereinbefore, the compounds of formula (I) may be converted into the salts 
thereof, particularly for pharmaceutical use, into the physiologically and pharmacologically 
acceptable salts thereof. These salts may on the one hand be in the form of the 
physiologically and pharmacologically acceptable acid addition salts of the compounds of 
formula (I) with inorganic or organic acids. On the other hand, if R is hydrogen, the 
compound of formula (I) may also be converted by reaction with inorganic bases into 
physiologically and pharmacologically acceptable salts with alkali or alkaline earth metal 
cations as counter ion. The acid addition salts may be prepared for example using 
hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, 
acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid. It
is also possible to use mixtures of the above-mentioned acids. The alkali and alkaline earth metal salts of the compound of formula (I) are preferably prepared using the alkali and alkaline earth metal hydroxides and hydrides thereof, of which the hydroxides and hydrides of the alkaline earth metals, particularly of sodium and potassium, are preferred and sodium and potassium hydroxide are particularly preferred.

If desired, the compounds of general formula (I) may be converted into the salts thereof, particularly, for pharmaceutical use, into the pharmacologically acceptable acid addition salts with an inorganic or organic acid. Suitable acids include for example succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid or citric acid. It is also possible to use mixtures of the above-mentioned acids.

Unless specifically indicated, throughout the specification and the appended claims, a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc…) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.

Hence the invention relates to the compounds in question, optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, in the form of the tautomers as well as in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids - such as for example acid addition salts with hydrohalic acids - for example hydrochloric or hydrobromic acid or organic acids - such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.

The compounds according to the invention may optionally occur as racemates, but they may also be obtained as pure enantiomers / diastereomers.

The invention relates to the compounds in question, optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, in the form of the tautomers as well as in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids - such as for example acid addition salts with hydrohalic acids - for example hydrochloric or hydrobromic acid or organic acids - such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.
The compounds according to formula (I) according to the invention have the meanings hereinbefore whereas in particular the preferred embodiments defined by R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, R₁₉, R₂₀, R₂₁, R₂₂, A, Li, L₂, Z, Q, and n in each case are independently selected of one another.

**Therapeutic applications**

The above exemplary substances have been tested for binding to CCR2 using a binding assay as outlined herein below:

**Cell culture:**

THP-1 cells (human acute monocytic leukaemia cells) were cultured under standardized conditions at 37 °C and 5 % CO₂ in a humidified incubator. THP-1 cells were cultivated in RPMI 1640 medium (Gibco 21875) containing 1 % MEM-NEAA (Gibso 11140) 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES and 1.0 mM sodium pyruvate, 90 %; 10 % fetal calf serum (FCS Gibco 10500-064).

Membranes were prepared from THP-1 cells. THP-1 cells were centrifuged at 300xg at 4°C for 10 min. The cell pellet was resuspended in Phosphate Buffer Saline (PBS, including 10 μM Pefabloc and a protease inhibitor mix 'complete', Boehringer Mannheim (1 tablet/50 ml)), to a concentration of 80 cells/ml. The membrane preparation was performed by disrupting the cells by nitrogen decomposition (at 50 bar, for 1h) in a "Nitrogen Bombe" (Parr Instrument). Cell debris was removed by centrifugation (800xg at 4°C, 1 min). The supernatant was centrifuged at 80000xg, 4°C for 30 min to sediment the cell membranes. Usually 50 mg of protein (Bradford assay) were yielded from 1x10⁸E9 cells. The membranes were resuspended in 25 mM HEPES, 25 mM MgCl₂, 1 mM CaCl₂, 10 % Glycerine for storage in aliquots at -80 °C in 25 mM HEPES, 25 mM MgCl₂, 1 mM CaCl₂, 10 % Glycerine and stored at -80°C.

**Receptor membrane binding assay:**

Perkin Elmer NEX 332 Jod 125 MCP-1, Stock: 2200 Ci/mmol solved in 2000 μl assay buffer, stored at -20°C. THP-1 membrane were adjusted with 25 mM HEPES, pH 7.2; 5 mM MgCl₂; 0.5 mM CaCl₂; 0.2 % BSA assay buffer to a concentration of 2.5 μg/15 μl.

Amersham Biosciences PVT-WGA Beads (RPNQ0001) were adjusted with assay buffer to a concentration of 0.24 mg/30 μl. For preparation of the membrane-bead-suspension membranes and beads were incubated for 30 min at RT under rotation (60 rpm) with a ratio of 1:2. Test compounds dissolved in 100 % DMSO to a concentration of 10 mM and are further diluted with 100 % DMSO to 1 mM. All additional compound dilutions were obtained with assay buffer, final 1% DMSO. Compounds, membrane-bead-suspension and [125I]MCP-1 (ca. 25000 cpm/10 μl) were incubated. Bound radioactivity was determined by scintillation counter after 8h. Determination of affinity of test compounds (dissociation
constant $h_{Ki}$ is calculated by iterative fitting of experimental data using the "easy sys"
program, which is based on law of mass action (Schittkowski K. (1994), Numerische

All of the referenced examples have been found to have an activity in this assay of 10 µM or
less.

<table>
<thead>
<tr>
<th>Example</th>
<th>$h_{Ki}$ [nM]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>60</td>
</tr>
<tr>
<td>2</td>
<td>40</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Example</th>
<th>$h_{Ki}$ [nM]</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Example</th>
<th>$h_{Ki}$ [nM]</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Example</th>
<th>$h_{Ki}$ [nM]</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>27</td>
</tr>
<tr>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>11</td>
<td>16</td>
</tr>
<tr>
<td>12</td>
<td>0.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Example</th>
<th>$h_{Ki}$ [nM]</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>35</td>
</tr>
<tr>
<td>14</td>
<td>5</td>
</tr>
<tr>
<td>15</td>
<td>6</td>
</tr>
<tr>
<td>16</td>
<td>3</td>
</tr>
<tr>
<td>17</td>
<td>73</td>
</tr>
<tr>
<td>18</td>
<td>7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Example</th>
<th>$h_{Ki}$ [nM]</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>9</td>
</tr>
<tr>
<td>20</td>
<td>54</td>
</tr>
<tr>
<td>21</td>
<td>41</td>
</tr>
<tr>
<td>22</td>
<td>4</td>
</tr>
<tr>
<td>23</td>
<td>128</td>
</tr>
</tbody>
</table>

Based on the ability of the substances described by formula (I) to effectively bind to CCR2 a
range of therapeutic applications can be envisaged. The present invention provides a method
for modulating or treating at least one MCP-1 related disease, in a cell, tissue, organ, animal,
or patient, as known in the art or as described herein, using at least one CCR2 antagonist of
the present invention. The present invention also provides a method for modulating or treating
at least one MCP-1 related disease, in a cell, tissue, organ, animal, or patient including, but
not limited to, at least one of malignant disease, metabolic disease, an immune or
inflammatory related disease, a cardiovascular disease, an infectious disease, or a neurologic
disease. Such conditions are selected from, but not limited to, diseases or conditions
mediated by cell adhesion and/or angiogenesis. Such diseases or conditions include an
immune disorder or disease, a cardiovascular disorder or disease, an infectious, malignant,
and/or neurologic disorder or disease, or other known or specified MCP-1 related conditions.
In particular, the CCR2 antagonists are useful for the treatment of diseases that involve
inflammation such as COPD, angiogenesis such as disease of the eye and neoplastic disease,
tissue remodeling such as restenosis, and proliferation of certain cells types particularly
epithelial and squamous cell carcinomas. Particular indications include use in the treatment of
atherosclerosis, restenosis, cancer metastasis, rheumatoid arthritis, diabetic retinopathy and
macular degeneration. The antagonists may also be useful in the treatment of various fibrotic
diseases such as idiopathic pulmonary fibrosis, diabetic nephropathy, hepatitis, and cirrhosis. Thus, the present invention provides a method for modulating or treating at least one CCR2 related disease, in a cell, tissue, organ, animal, or patient, as known in the art or as described herein, using at least one CCR2 antagonist of the present invention. Particular indications are discussed below:

**Pulmonary Diseases**

The present invention also provides a method for modulating or treating at least one malignant disease in a cell, tissue, organ, animal or patient, including, but not limited to, at least one of: pneumonia; lung abscess; occupational lung diseases caused be agents in the form or dusts, gases, or mists; asthma, bronchiolitis fibrosa obliterans, respiratory failure, hypersensitivity diseases of the lungs including hypersensitivity pneumonitis (extrinsic allergic alveolitis), allergic bronchopulmonary aspergillosis, and drug reactions; adult respiratory distress syndrome (ARDS), Goodpasture's Syndrome, chronic obstructive airway disorders (COPD), idiopathic interstitial lung diseases such as idiopathic pulmonary fibrosis and sarcoidosis, desquamative interstitial pneumonia, acute interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease, idiopathic bronchiolitis obliterans with organizing pneumonia, lymphocytic interstitial pneumonitis, Langerhans' cell granulomatosis, idiopathic pulmonary hemosiderosis; acute bronchitis, pulmonary alveolar, proteinosis, bronchiectasis, pleural disorders, atelectasis, cystic fibrosis, and tumors of the lung, and pulmonary embolism.

**Malignant Diseases**

The present invention also provides a method for modulating or treating at least one malignant disease in a cell, tissue, organ, animal or patient, including, but not limited to, at least one of: leukemia, acute leukemia, acute lymphoblastic leukemia (ALL), B-cell, T-cell or FAB ALL, acute myeloid leukemia (AML), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), hairy cell leukemia, myelodyplastic syndrome (MDS), a lymphoma, Hodgkin's disease, a malignant lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, Kaposi's sarcoma, colorectal carcinoma, pancreatic carcinoma, renal cell carcinoma, breast cancer, nasopharyngeal carcinoma, malignant histiocytosis, paraneoplastic syndrome/hypercalcemia of malignancy, solid tumors, adenocarcinomas, squamous cell carcinomas, sarcomas, malignant melanoma, particularly metastatic melanoma, hemangioma, metastatic disease, cancer related bone resorption, cancer related bone pain, and the like.

**Immune Related Diseases**

The present invention also provides a method for modulating or treating at least one immune
related disease, in a cell, tissue, organ, animal, or patient including, but not limited to, at least one of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondilitis, gastric ulcer, seronegative arthropathies, osteoarthritis, inflammatory bowel disease, ulcerative colitis, systemic lupus erythematosus, antiphospholipid syndrome, iridocyclitis/uveitis/loptisptic neuritis, idiopathic pulmonary fibrosis, systemic vasculitis/wegener's granulomatosis, sarcoidosis, orchitis/vasectomy reversal procedures, allergic glomerulonephritis, asthma, allergic rhinitis, eczema, allergic contact dermatitis, allergic conjunctivitis, hypersensitivity pneumonitis, transplants, organ transplant rejection, graft-versus-host disease, systemic inflammatory response syndrome, sepsis syndrome, gram positive sepsis, gram negative sepsis, culture negative sepsis, fungal sepsis, neutropenic fever, urosepsis, meningococcemia, trauma/hem—hage, burns, ionizing radiation exposure, acute pancreatitis, adult respiratory distress syndrome, rheumatoid arthritis, alcohol-induced hepatitis, chronic inflammatory pathologies, sarcoidosis, Crohn's pathology, sickle cell anemia, diabetes, nephrosis, atopic diseases, hypersensitivity reactions, allergic rhinitis, hay fever, perennial rhinitis, conjunctivitis, endometriosis, asthma, urticaria, systemic anaphalaxis, dermatitis, pernicious anemia, hemolytic diseases, thrombocytopenia, graft rejection of any organ or tissue, kidney transplant rejection, heart transplant rejection, liver transplant rejection, pancreas transplant rejection, lung transplant rejection, bone marrow transplant (BMT) rejection, skin allograft rejection, cartilage transplant rejection, bone graft rejection, small bowel transplant rejection, fetal thymus implant rejection, parathyroid transplant rejection, xenograft rejection of any organ or tissue, allograft rejection, anti-receptor hypersensitivity reactions, Graves disease, Raynoud's disease, type B insulin-resistant diabetes, asthma, myasthenia gravis, antibody-mediatated cytotoxicity, type IU hypersensitivity reactions, systemic lupus erythematosus, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes syndrome, antiphospholipid syndrome, pemphigus, scleroderma, mixed connective tissue disease, idiopathic Addison's disease, diabetes mellitus, chronic active hepatitis, primary biliary cirrhosis, vitiligo, vasculitis, post-MI cardiomyopathy syndrome, type IV hypersensitivity, contact dermatitis, hypersensitivity pneumonitis, allograft rejection, granulomas due to intracellular organisms, drug sensitivity, metabolic/idiopathic, Wilson's disease, hemachromatosis, alpha-1-antitrypsin deficiency, diabetic retinopathy, hashimoto's thyroiditis, osteoporosis, hypothalamic-pituitary-adrenal axis evaluation, primary biliary cirrhosis, thyroiditis, encephalomyelitis, cachexia, cystic fibrosis, neonatal chronic lung disease, chronic obstructive pulmonary disease (COPD), familial hemophagocytic lymphohistiocytosis, dermatologic conditions, psoriasis, alopecia, nephrotic syndrome, nephritis, glomerular nephritis, acute renal failure, hemodialysis, uremia, toxicity, preeclampsia, OKT3 therapy, anti-CD3 therapy, cytokine therapy, chemotherapy, radiation therapy (e.g., including but not limited to asthma, anemia, cachexia, and the like), chronic
salicylate intoxication, and the like.

Cardiovascular Diseases
The present invention also provides a method for modulating or treating at least one cardiovascular disease in a cell, tissue, organ, animal, or patient, including, but not limited to, at least one of cardiac 25 stun syndrome, myocardial infarction, congestive heart failure, stroke, ischemic stroke, hemorrhage, arteriosclerosis, atherosclerosis, restenosis, diabetic atherosclerotic disease, hypertension, arterial hypertension, renovascular hypertension, syncope, shock, syphilis of the cardiovascular system, heart failure, cor pulmonale, primary pulmonary hypertension, cardiac arrhythmias, atrial ectopic beats, atrial flutter, atrial fibrillation (sustained or paroxysmal), post perfusion syndrome, cardiopulmonary bypass inflammation response, chaotic or multifocal atrial tachycardia, regular narrow QRS tachycardia, specific arrhythmias, ventricular fibrillation, His bundle arrhythmias, atrioventricular block, bundle branch block, myocardial ischemic disorders, coronary artery disease, angina pectoris, myocardial infarction, cardiomyopathy, dilated congestive cardiomyopathy, restrictive cardiomyopathy, valvular heart diseases, endocarditis, pericardial disease, cardiac tumors, aortic and peripheral aneurysms, aortic dissection, inflammation of the aorta, occlusion of the abdominal aorta and its branches, peripheral vascular disorders, occlusive arterial disorders, peripheral atherosclerotic disease, thromboangiitis obliterans, functional peripheral arterial disorders, Raynaud's phenomenon and disease, acrocyanosis, erythromelalgia, venous diseases, venous thrombosis, varicose veins, arteriovenous fistula, lymphedema, lipedema, unstable angina, reperfusion injury, post pump syndrome, ischemia-reperfusion injury, and the like. Such a method can optionally comprise administering an effective amount of a composition or pharmaceutical composition comprising at least one CCR2 antagonist to a cell, tissue, organ, animal or patient in need of such modulation, treatment or therapy.

Neurologic Diseases
The present invention also provides a method for modulating or treating at least one neurologic disease in a cell, tissue, organ, animal or patient, including, but not limited to, at least one of: Inflammatory pain, chronic pain, Neuropathic pain such as low back pain, hip pain, leg pain, non-herpetic neuralgia, post herpetic neuralgia, diabetic neuropathy, nerve injury-induced pain, acquired immune deficiency syndrome (AIDS) related neuropathic pain, head trauma, toxin and chemotherapy caused nerve injuries, phantom limb pain, multiple sclerosis, root avulsions, painful traumatic mononeuropathy, painful polyneuropathy, thalamic pain syndrome, post-stroke pain, central nervous system injury, post surgical pain, carpal tunnel syndrome, trigeminal neuralgia, post mastectomy syndrome, postthoracotomy syndrome, stump pain, repetitive motion pain, neuropathic pain associated hyperalgesia and allodynia, alcoholism and other drug-induced pain, neurodegenerative diseases, multiple
sclerosis, migraine headache, AIDS dementia complex, demyelinating diseases, such as multiple sclerosis and acute transverse myelitis; extrapyramidal and cerebellar disorders' such as lesions of the corticospinal system; disorders of the basal ganglia or cerebellar disorders; hyperkinetic movement disorders such as Huntington's Chorea and senile chorea; drug-induced movement disorders, such as those induced by drugs which block CNS dopamine receptors; hypokinetic movement disorders, such as Parkinson's disease; Progressive supranuclear Palsy; structural lesions of the cerebellum; spinocerebellar degenerations, such as spinal ataxia, Friedreich's ataxia, cerebellar cortical degenerations, multiple systems degenerations (Mencel, Dejerine-Thomas, Shi-Drager, and Machado-Joseph); systemic disorders (Refsum's disease, abetalipoproteinemia, ataxia, telangiectasia, and mitochondrial multi-system disorder); demyelinating core disorders, such as multiple sclerosis, acute transverse myelitis; and disorders of the motor unit' such as neurogenic muscular atrophies (anterior horn cell degeneration, such as amyotrophic lateral sclerosis, infantile spinal muscular atrophy and juvenile spinal muscular atrophy); Alzheimer's disease; Down's Syndrome in middle age; Diffuse Lewy body disease; Senile Dementia of Lewy body type; Wernicke-Korsakoff syndrome; chronic alcoholism; Creutzfeldt-Jakob disease; Subacute sclerosing panencephalitis, Hallerrorden-Spatz disease; and Dementia pugilistica, and the like.

Fibrotic Conditions

In addition to the above described conditions and diseases, the present invention also provides a method for modulating or treating fibrotic conditions of various etiologies such as liver fibrosis (including but not limited to alcohol-induced cirrhosis, viral-induced cirrhosis, autoimmune-induced hepatitis); lung fibrosis (including but not limited to scleroderma, idiopathic pulmonary fibrosis); kidney fibrosis (including but not limited to scleroderma, diabetic nephritis, glomerular nephritis, lupus nephritis); dermal fibrosis (including but not limited to scleroderma, hypertrophic and keloid scarring, burns); myelofibrosis; Neurofibromatosis; fibroma; intestinal fibrosis; and fibrotic adhesions resulting from surgical procedures.

The present invention also provides a method for modulating or treating at least one wound, trauma or tissue injury or chronic condition resulting from or related thereto, in a cell, tissue, organ, animal or patient, including, but not limited to, at least one of: bodily injury or a trauma associated with surgery including thoracic, abdominal, cranial, or oral surgery; or wherein the wound is selected from the group consisting of aseptic wounds, contused wounds, incised wounds, lacerated wounds, non-penetrating wounds, open wounds, penetrating wounds, perforating wounds, puncture wounds, septic wounds, infarctions and subcutaneous wounds; or wherein the wound is selected from the group consisting of ischemic ulcers, pressure sores, fistulae, severe bites, thermal burns and donor site wounds; or wherein the wound is an aphthous wound, a traumatic wound or a herpes associated wound. Donor site wounds are wounds which e.g. occur in connection with removal of hard tissue from one part
of the body to another part of the body e.g. in connection with transplantation. The wounds resulting from such operations are very painful and an improved healing is therefore most valuable. Wound fibrosis is also amenable to CCR2 antagonist therapy as the first cells to invade the wound area are neutrophils followed by monocytes which are activated by macrophages. Macrophages are believed to be essential for efficient wound healing in that they also are responsible for phagocytosis of pathogenic organisms and a clearing up of tissue debris. Furthermore, they release numerous factors involved in subsequent events of the healing process. The macrophages attract fibroblasts which start the production of collagen. Almost all tissue repair processes include the early connective tissue formation, a stimulation of this and the subsequent processes improve tissue healing, however, overproduction of connective tissue and collagen can lead to a fibrotic tissue characterized as inelastic and hypoxic. The CCR2 antagonist of the invention can be used in methods for modulating, treating or preventing such sequelae of wound healing.

Other Therapeutic Uses of CCR2 antagonists

The present invention also provides a method for modulating or treating at least one infectious disease in a cell, tissue, organ, animal or patient, including, but not limited to, at least one of: acute or chronic bacterial infection, acute and chronic parasitic or infectious processes, including bacterial, viral and fungal infections, HIV infection, HIV neuropathy, meningitis, hepatitis (A, B or C, or the like), septic arthritis, peritonitis, pneumonia, epiglottitis, e. coli 0157:h7, hemolytic uremic syndrome/thrombo lytic thrombocytopenic purpura, malaria, dengue hemorrhagic fever, leishmaniasis, leprosy, toxic shock syndrome, streptococcal myositis, gas gangrene, mycobacterium tuberculosis, mycobacterium avium intracellulare, Pneumocystis carinii pneumonia, pelvic inflammatory disease, orchitislepidydimitis, legionella, lyme disease, influenza a, epstein-barr virus, vital-associated hemaphagocytic syndrome, vital encephalitisiasptic meningitis, and the like.

Any method of the present invention can comprise administering an effective amount of a composition or pharmaceutical composition comprising at least one CCR2 antagonist to a cell, tissue, organ, animal or patient in need of such modulation, treatment or therapy.

Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like.

Combinations

The compounds of formula (I) may be used on their own or in conjunction with other active substances of formula (I) according to the invention. If desired the compounds of formula (I) may also be used in combination with other pharmacologically active substances. It is preferable to use for this purpose active substances selected for example from among
B2-adrenoceptor-agonists (short and lon-acting betamimetics), anti-cholinergics (short and lon-acting), anti-inflammatory steroids (oral and topical corticosteroids), cromoglycate, methylxanthine, dissociated-glucocorticoidmimetics, PDE3 inhibitors, PDE4- inhibitors, PDE7- inhibitors, LTD4 antagonists, EGFR- inhibitors, Dopamine agonists, statins, PAF antagonists, Lipoxin A4 derivatives, FPRL1 modulators, LTB4-receptor (BLT1, BLT2) antagonists, Histamine H1 receptor antagonists, Histamine H4 receptor antagonists, dual Histamine H1/H3-receptor antagonists, PI3-kinase inhibitors, inhibitors of non-receptor tyrosine kinases as for example LYN, LCK, SYK (spleen tyrosine kinase-inhibitors), ZAP-70, FYN, BTK or ITK, inhibitors of MAP kinases as for example p38, ERK1, ERK2, JNK1, JNK2, JNK3 or SAP, inhibitors of the NF-kappaB signalling pathway as for example IKK2 kinase inhibitors, iNOS inhibitors (inducible nitric oxide synthase-inhibitors), MRP4 inhibitors, leukotriene antagonists, leukotriene biosynthese inhibitors as for example 5-Lipoxygenase (5-LO) inhibitors, cPLA2 inhibitors, Leukotriene A4 Hydrolase inhibitors or FLAP inhibitors, non-steroidal antiinflammatory drugs (NSAIDs) including COX-2 inhibitors, CRTH2 antagonists, DP1-receptor modulators, Thromboxane receptor antagonists, CCR1 antagonists, CCR4 antagonists, CCR5 antagonists, CCR6 antagonists, CCR7 antagonists, CCR8 antagonists, CCR9 antagonists, CCR10 antagonists, CCR1 l antagonists, CXCR1 antagonists, CXCR2 antagonists, CXCR3 antagonists, CXCR4 antagonists, CXCR5 antagonists, CXCR6 antagonists, CX3CR1 antagonists, Neurokinin (NK1, NK2) antagonists, Sphingosine 1-Phosphate receptor modulators, Sphingosine 1phosphate lyase inhibitors, Adenosine receptor modulators as for example A2a-agonists, modulators of purinergic receptors as for example P2X7 inhibitors, Histone Deacetylase (HDAC) activators, Bradykinin (BK1, BK2) antagonists, TACE inhibitors, PPAR gamma modulators, Rho-kinase inhibitors, interleukin 1-beta converting enzyme (ICE) inhibitors, Toll-Like receptor (TLR) modulators, HMG-CoA reductase inhibitors, VLA-4 antagonists, ICAM-1 inhibitors, SHIP agonists, GABAAa receptor antagonist, ENaC-inhibitors, Melanocortin receptor (MC1R, MC2R, MC3R, MC4R, MC5R) modulators, CGRP antagonists, Endothelin antagonists, TNFalpha antagonists, anti-TNF antibodies, anti-GM-CSF antibodies, anti-CD46 antibodies, anti-IL-1 antibodies, anti-IL-2 antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, anti-IL-13 antibodies, anti-IL-4/IL-13 antibodies, anti-TSLP antibodies, anti-OX40 antibodies, mucoregulators, immunotherapeutic agents, compounds against swelling of the airways, compounds against cough, antiviral drugs, opiate receptor agonists, cannabinoid agonists, sodium channel blockers, N-type calcium channel blockers, serotonergic and noradrenergic modulators, proton pump inhibitors, local anesthetics, VR1 agonists and antagonists, Nicotinic acetylcholine receptor agonists, P2X3 receptor antagonists, NGF agonists and antagonists, NMDA antagonist, potassium channel modulators, GABA modulators, serotonergic and noradrenergic modulators, anti-migraine drugs. The invention also encompasses combinations of three active substances, each selected from one of the abovemenioned categories of compounds. Said list is not considered to have a limiting character.
The betamimetics used are preferably compounds selected from among albuterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, arformoterol, zinterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levalbutamol, mabuterol, melaadrine, metaproterenol, orciprenaline, pirbuterol, procatelol, reproterol, rimetrol, ritodrine, salmeterol, salmefamol, soteronol, sulphonterol, tiaramide, terbutaline, tolubuterol, CHF-1035, HOKU-81, KUL-1248, 3-(4-{6-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)ethylamino]-hexyloxy}-butyl)-benzyl-sulphonamide, 5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one, 4-hydroxy-7-[2-{3-(2-phenylethoxy)propyl sulphonyl}ethyl-amino]-2(3H)-benzothiazole-1-one, 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butyramino]ethanol, 1-[3-(4-methoxybenzyl-amino)-4-hydroxyphenyl]-2-{4-(1-benzimidazolyl)-2-methyl-2-butyramino}ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoazin-8-yl]-2-[3-(4-N,N-dimethyaminophenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol. 5-hydroxy-8-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoazin-3-(4H)-one, 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert-butyramino)ethanol, 6-hydroxy-8-{1-hydroxy-2-[4-(methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl]-4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8-{1-hydroxy-2-[4-(phenoxy-acetate)ethyl]-1,1-dimethyl-ethylamino)-ethyl]-4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8-{1-hydroxy-2-[4-(phenoxy-acetic acid)ethyl]-1,1-dimethyl-ethylamino)-ethyl]-4H-benzo[1,4]oxazin-3-one, 8-{2-[1,1-dimethyl-2-(2,4,6-trimethylphenyl)-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8-{1-hydroxy-2-[2-(4-hydroxy-phenyl)]-1,1-dimethyl-ethylamino)-ethyl]-4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8-{1-hydroxy-2-[2-(4-hydroxy-phenyl)]-1,1-dimethyl-ethylamino)-ethyl]-4H-benzo[1,4]oxazin-3-one, 8-{2-[2-(4-ethoxy-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one, 8-{2-[2-(3,4-difluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one and 1-{4-ethoxy-carbonylamino-3-cyano-5-fluorophenyl}-2-(tert-butyramino)ethanol, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.

Preferably the beta mimetics are selected from among bambuterol, bitolterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, pirbuterol, procatelol, reproterol,
salmeterol, sulphonterol, terbutaline, tolubuterol, 3-(4-{6-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzenesulphonamide, 5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one, 4-hydroxy-7-[2-[(3-(2-phenylethoxy)propyl) sulphonyl] ethyl]-amino [ethyl]-2(3H)-benzothiazolone, 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino] ethano. 1-[3-(4-methoxybenzyl-amino)-4-hydroxyphenyl]-2-[2-(1-benzimidazolyl)-2-methyl-2-butylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino] ethano. 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-meth
butyloxyphenyl)-2-methyl-2-propylamino]ethanol, 6-hydroxy-8- {1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(4-phenoxy-acetate ethyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(4-phenoxy-acetic acid)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 8-{2-[1,1-dimethyl-2-(2,4,6-trimethylphenyl)-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(4-hydroxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(4-isopropyl-phenyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 8-{-2-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(4-hydroxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(4-isopropyl-phenyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 8-{-2-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(4-hydroxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(4-isopropyl-phenyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 8-{-2-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(4-hydroxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(4-isopropyl-phenyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 8-{-2-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one, and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.

Of these betamimetics those which are particularly preferred according to the invention are formoterol, salmeterol, 3-(4-{-6-[2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyloxy} -butyl)-benzenesulphonamide, 6-hydroxy-8- {1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl} -4H-benzo[1,4]oxazin-3-one, 6-hydroxy-8- {1-hydroxy-2-[2-(ethyl-4-phenoxy-acetate)- ethylamino]-2-methyl-propyl} -phenoxy-butyric acid, 8-{-2-[2-(3,4-difluoro-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl} -6-hydroxy-4H-benzo[1,4]oxazin-3-one and 1-[2H-5-hydroxy-3-oxo-4H-l,4-benzoaxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butilamino}ethanol, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.
According to the invention the acid addition salts of the betamimetics are preferably selected from among hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydroiumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonat. Of the above-mentioned acid addition salts the salts of hydrochloric acid, methanesulphonic acid, benzoic acid and acetic acid are particularly preferred according to the invention.


In the above-mentioned salts the cations tiotropium, oxitropium, flutropium, ipratropium, glycopyrronium and trosptomol are the pharmacologically active ingredients. As anions, the above-mentioned salts may preferably contain chloride, bromide, iodide, sulphate, phosphates, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulphonate, while chloride, bromide, iodide, sulphate, methanesulphonate or p-toluenesulphonate are preferred as counter-ions. Of all the salts, the chlorides, bromides, iodides and methanesulphonate are particularly preferred.
Of particular importance is tiotropium bromide. In the case of tiotropium bromide the pharmaceutical combinations according to the invention preferably contain it in the form of the crystalline tiotropium bromide monohydrate, which is known from WO 02/30928. If the tiotropium bromide is used in anhydrous form in the pharmaceutical combinations according to the invention, it is preferable to use anhydrous crystalline tiotropium bromide, which is known from WO 03/00265.

Corticosteroids used here are preferably compounds selected from among prednisolone, prednisone, butoxocortpropionate, flunisolide, beclometasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, dexamethasone, betamethasone, defiazacort, RPR-106541, NS-126, (S)-fluoromethyl 6,9-difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxo-androsta-1,4-diene-17-carbothionate and (S)-(2-oxo-tetrahydro-furan-3-S-yl) 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-propionyloxy-androsta-1,4-diene-17-carbothionate, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the salts and derivatives, solvates and/or hydrates thereof.

Particularly preferred is the steroid selected from among flunisolide, beclometasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, dexamethasone, NS-126, (S)-fluoromethyl 6,9-difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxo-androsta-1,4-diene-17-carbothionate and (S)-(2-oxo-tetrahydro-furan-3-S-yl) 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-propionyloxy-androsta-1,4-diene-17-carbothionate, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the salts and derivatives, solvates and/or hydrates thereof.

Particularly preferred is the steroid selected from among budesonide, fluticasone, mometasone, ciclesonide and (S)-fluoromethyl 6,9-difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxo-androsta-1,4-diene-17-carbothionate, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the salts and derivatives, solvates and/or hydrates thereof.

Any reference to steroids includes a reference to any salts or derivatives, hydrates or solvates thereof which may exist. Examples of possible salts and derivatives of the steroids may be: alkali metal salts, such as for example sodium or potassium salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates thereof.
PDE4 inhibitors which may be preferably compounds selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirimilast, aroflyUn, atizoram, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-1 1294A, Cl-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370, N-(3,5-dichloro-1-oxo-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide, (-)-[4aR*,10bS*]-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo [s][1,6]naphthyridin-6-yl] -N,N-diisopropylbenzamide, (R)-(+) 1-(4-bromobenzyl)-4-[(3-cyclopentoxy)-4-methoxyphenyl]-2-pyrrolidone, 3-(cyclopent oxy-4-methoxyphenyl)- 1-(4-N'-[N-2-cyano-S-methyl-isothioureido]benzyl)-2-pyrrolidone, cis[4-cyano-4-(3-cyclopent oxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid], 2-carbomethoxy-4-cyano-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexane-1-one, cis[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-ol], (R)-(+)-ethyl[4-(3-cyclopent oxy-4-methoxyphenyl)pyrrolidin-2-ylidene]acetate, (S)-(+)ethyl[4-(3-cyclopent oxy-4-methoxyphenyl)pyrrolidin-2-ylidene] acetate, 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine and 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3,4-c]-l,2,4-triazolo[4,3-a]pyridine, optionally in the form of the racemates, enantiomers or diastereomers and optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof.

The PDE4-inhibitor used are preferably compounds selected from among enprofyllin, roflumilast, ariflo (cilomilast), aroflyUn, atizoram, AWD-12-281 (GW-842470), T-440, T-2585, PD-168787, V-1 1294A, Cl-1018, CDC-801, D-22888, YM-58997, Z-15370, N-(3,5-dichloro-1-oxo-pyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide, cis[4-cyano-4-(3-cyclopent oxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid], 2-carbomethoxy-4-cyano-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexane-1-one, cis[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-ol], 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine and 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, optionally in the form of the racemates, enantiomers or diastereomers and optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof.

By acid addition salts with pharmacologically acceptable acids which the above-mentioned PDE4-inhibitors might be in a position to form are meant, for example, salts selected from among the hydrochloride, hydrobromide, hydroiodide, hydro sulphate, hydrophosphate, hydroxylisuphophate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydroiumurate, hydrotartrate, hydroxalate, hydrosuccininate, hydrobenzoate and hydro-p-toluenesulphonate, preferably hydrochloride, hydrobromide, hydro sulphate, hydrophosphate, hydroiumurate and hydromethanesulphonate.
LTD4-antagonists which may be used are preferably compounds selected from among montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707, L-733321, 1-((R)-(3-(2-(6,7-difluoro-2-quinoliny1)ethenyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methylcyclopropane-acetic acid, 1-(((R)-3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methylcyclopropane-acetic acid and [2-[2-(4-tert-butyl-2-thiazolyl)-5-benzofuranyl]oxymethyl]phenyl]acetic acid, optionally in the form of the racemates, enantiomers or diastereomers, optionally in the form of the pharmacologically acceptable acid addition salts and optionally in the form of the salts and derivatives, solvates and/or hydrates thereof.

Preferably the LTD4-antagonist is selected from among montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707 and L-733321, optionally in the form of the racemates, enantiomers or diastereomers, optionally in the form of the pharmacologically acceptable acid addition salts and optionally in the form of the salts and derivatives, solvates and/or hydrates thereof.

Particularly preferably the LTD4-antagonist is selected from among montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001 and MEN-91507 (LM-1507), optionally in the form of the racemates, enantiomers or diastereomers, optionally in the form of the pharmacologically acceptable acid addition salts and optionally in the form of the salts and derivatives, solvates and/or hydrates thereof.

By acid addition salts with pharmacologically acceptable acids which the LTD4-antagonists may be capable of forming are meant, for example, salts selected from among the hydrochloride, hydrobromide, hydroiodide, hydro sulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydroi umarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-tolu enesulphonate, preferably hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate. By salts or derivatives which the LTD4-antagonists may be capable of forming are meant, for example: alkali metal salts, such as, for example, sodium or potassium salts, alkaline earth metal salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.

EGFR-inhibitors which may be used are preferably compounds selected from among 4-[[3-chloro-4-fluorophenyl]amino]-6-[[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxy-quinazoline, 4-[[3-chloro-4-fluorophenyl]amino]-6-[[4-(N,N-
diethylamino)-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxy-quinazoline,
4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(morpholin-4-y1)-1-oxo-2-buten-1-yl]amino]-7-cyclopentyl-
oxy-quinazoline,
4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-([N,N-dimethylamino]-1-oxo-2-buten-1-yl]amino)]-
7-cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-
cyclopropylmethoxy-quinazoline,
yl] amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-
{[4-(5,5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-quinazoline, 4-[(3-
chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-
methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-
morpholin-4-yl)-ethoxy]-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-
fluoro-phenyl)amino]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-
fluoro-phenyl)amino]-6-1-(tert.-butyloxycarbonyl)-piperidin-4-yl)-7-methoxy-quinazoline,
4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexan-1-yl)-7-methoxy-
quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methanesulphonylamino-
cyclohexan-1-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-
(tetrahydropyran-3-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-
(1-methyl-piperidin-4-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-
{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yl]-7-methoxy-quinazoline, 4-[(3-chloro-4-
fluoro-phenyl)amino]-6-1-[(methoxymethyl)carbonyl]-piperidin-4-yl)-7-methoxy-
quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-1-(2-acetylamino-ethyl)-piperidin-
4-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-
(tetrahydropyran-4-yl)-7-ethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-
((S)-tetrahydrofuran-3-yl)-7-hydroxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-
(tetrahydropyran-4-yl)-7-(2-methanesulphonylamino-cyclohexan-1-yl)-7-methoxy-
quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-1-(2-acetylamino-ethyl)-piperidin-
4-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-
(tetrahydropyran-4-yl)-7-ethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-
{1-[(methoxymethyl)carbonyl]-piperidin-4-yl]-7-methoxy-quinazoline, 4-[(3-chloro-4-
fluoro-phenyl)amino]-6-(trans-4-methanesulphonyl-piperidin-4-yl)-7-ethoxy-quinazoline,
4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-[N-[(morpholin-4-yl)sulphonyl]-N-methyl-
amino]-cyclohexan-1-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-
{1-[(piperidin-1-yl)carbonyl]-piperidin-4-yl]-7-methoxy-quinazoline, 4-[(3-chloro-
4-fluoro-phenyl)amino]-6-(cis-4-{N-[((tetrahydropyran-4-yl)carbonyl]-N-methyl-
amino]-cyclohexan-1-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-
{(cis-4-[N-((morpholin-4-yl)sulphonyl]-N-methyl-aminocarbonyl-methyl-piperidin-
4-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-
aminocarbonyl-methyl-piperidin-4-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-
phenyl)amino]-6-(cis-4-{N-[(tetrahydropyran-4-yl)carbonyl]-N-methyl-aminocarby-
l-methyl-piperidin-4-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-
(cis-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-aminocarbonyl-methyl-piperidin-
4-yl)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-
ethanesulphonylamino-cyclohexan-1-yl)-7-methoxy-quinazoline, 4-[(3-chloro-
4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yl)-7-ethoxy-quinazoline,
4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yl)-7-(2-methoxy-
ethoxy)-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(1-(2-methoxy-acetyl)piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-acetamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-[(tetrahydropryan-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[{(piperidin-1-yl)carbonyl]-N-methyl-amino}]-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[{(4-methylpiperazin-1-yl)carbonyl]-N-methyl-amino}]-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(2-(2-oxopyrrolidin-1-yl)ethyl]-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-acetyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-isopropyloxycarbonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline. 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(2-methoxy-acetyl)-N-methyl-amino}]-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(N-methyl-N-2-methoxyethyl-amino)carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-ethyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(3-methoxypropyl-amino)-carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(N-methyl-N-2-methoxyethyl-amino)carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(1-ethyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(N-acetyl-N-methyl-amino)-carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(trans-4-methylaminocyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(N-acetyl-N-methyl-amino)-carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(trans-4-methylaminocyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(N-acetyl-N-methyl-amino)-carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(N-acetyl-N-methyl-amino)-carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline. 4-
[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-1-yloxy)-7-
methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-N-[(morpholin-4-
yl)carbonyl]-N-methyl-amin o]-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-
fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(S)-
tetrahydro furan-2-yl]methoxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-
methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluo-
ro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, Cetuximab,
Trastuzumab, ABX-EGF and Mab ICR-62, optionally in the form of the racemates,
enantiomers or diastereomers thereof, optionally in the form of the pharmacologically
acceptable acid addition salts, the solvates and/or hydrates thereof.

Preferred EGFR inhibitors are selected from among 4-[(3-chloro-4-fluorophenyl)amino]-6-
{(4-(morpholin-4-yl)-1-oxo-2-buten-1-yl)amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-
chloro-4-fluorophenyl)amino]-6-[(4-(N,N-diethylamino)-1-oxo-2-buten-1-yl)amino]-7-
eyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-[N-3-
dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxy-quinazoline, 4-[(R)-
(1-phenyl-ethyl)amino]-6-[(4-(morpholin-4-yl)-1-oxo-2-buten-1-yl)amino]-7-cyclopent-
loxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[2-(S)-6-methyl-2-oxo-morpholin-
4-yl]-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-
fluorophenyl)amino]-6-[(S)-(tetrahydrofuran-3-yloxy)-quinazoline, 4-[(3-chloro-4-
fluorophenyl)amino]-6-[(R)-2-methoxymethyl-6-oxo-morpholin-4-yl]-1-oxo-2-buten-1-
yl]amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-
[(R)-2-methoxymethyl-6-oxo-morpholin-4-yl]-1-oxo-2-buten-1-yl]amino)-7-cyclopropyl-
loxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-
4-yl)-ethoxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-[N-(2-
methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxy-
quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-
buten-1-yl)amino]-7-cyclopentloxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-
[(4-(N,N-bis-(2-methoxy-ethyl)-amino)-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmeth-
xy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-
4-yl)-ethoxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-[N-(2-
methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxy-
quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-
buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-
[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline,
4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)amino]-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)amino]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6,7-bis-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)-propyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(R)-(l-phenyl-ethyl)amino]-6-(4-hydroxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidine, 3-cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)amino]-7-ethoxy-quinoline, 4-[(3-chloro-4-(3-fluoro-benzyloxy)phenyl)amino]-6,7-bis-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[3-(morpholin-4-yl)-propyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(R)-(l-phenyl-ethyl)amino]-6-[(4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl)amino]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-(5-[(2-methanesulphonyl-ethyl)amino]methyl)-furan-2-yl)quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-(5.5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl)amino]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methanesulphonylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(dimethylamino)sulphonyl]carbonyl-cyclohexan-1-yloxy} -7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-(2-acetylamino-ethyl)-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[1-(tert.-butyloxycarbonyl)piperidin-4-yloxy] -7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-amino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(4-[N,N-bis-(2-methoxy-ethyl)amino]-1-oxo-2-buten-1-yl)amino]-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)amino]-7-ethoxy-quinoline, 4-[(3-chloro-4-(3-fluoro-benzyloxy)phenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)amino]-7-ethoxy-quinoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)amino]-7-ethoxy-quinoline, 4-[(3-chloro-4-(3-fluoro-benzyloxy)phenyl)amino]-6-(trans-4-amino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-(2-acetylamino-ethyl)-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[1-(tert.-butyloxycarbonyl)piperidin-4-yloxy] -7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{trans-4-[(dimethylamino)sulphonyl]carbonyl-cyclohexan-1-yloxy} -7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-3-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)amino]-7-ethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)amino]-7-ethoxy-quinazoline.
4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-acetylamino-ethoxy)-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methanesulphonylamino-ethoxy)-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(piperidin-1-yl)carbonyl]-piperidin-4-yloxy] -7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-amino-carbonylmethyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[((tetrahydropyran-4-yl)carbonyl]-N-methyl-amino} -cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[morpholin-4-yl)sulphonyl]-N-methyl-amino} -cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[morpholin-4-yl]carbonyl]-N-methyl-amino} -cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[(morpholin-4-yl)sulphonyl]-N-methyl-amino} -cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(2-methoxy-acetyl)-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[morpholin-4-yl]carbonyl]-N-methyl-amino} -cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[morpholin-4-yl)sulphonyl]-N-methyl-amino} -cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[morpholin-4-yl]carbonyl]-N-methyl-amino} -cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[morpholin-4-yl)sulphonyl]-N-methyl-amino} -cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[morpholin-4-yl)carbonyl]-N-methyl-amino} -cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N-[morpholin-4-yl)sulphonyl]-N-methyl-amino} -cyclohexan-1-yloxy)-7-methoxy-quinazoline.
yl)carbonyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6- {1-[(S,S)-(2-oxa-5-aza-bicyclo[2,2,1]hept-5-yl)carbonyl]-piperidin-4-yloxy} -7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6- (1-ethyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6- (1-[(2-methoxyethyl)carbonyl]-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6- (1-ethyl-piperidin-4-yloxy)-7-methoxy-quinazoline, and Cetuximab, optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts, the solvates and/or hydrates thereof.

Preferable the EGFR-inhibitors are selected from among 4-[(3-chloro-4-fluorophenyl)amino]-6- {4-[(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6- {[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, and Cetuximab, optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts, the solvates and/or hydrates thereof.
pyrrolo[2,3-d]pyrimidine, 3-cyano-4-[3-chloro-4-fluorophenyl]amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-ethoxy-quinoline, 4-[(R)-(1-phenylethyl)amino]-6-{4-[(R)-6-methyl-2-oxo-morpholin-4-yl]-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-{4-(2-oxo-morpholin-4-yl)piperidin-1-yl]-ethoxy}-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(trans-4-amino-cyclohexan-1-yl)oxy]-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(trans-4-methanesulphonylcarbonylpiperidin-1-yl)-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(tetrahydropryan-3-yl)-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-{1-[(morpholin-4-yl)carbonylpiperidin4-yl]oxy}-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(piperidin-3-yl)-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-{trans-4-[(morpholin-4-yl)carbonylamino]-cyclohexan-1-yl]oxy}-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(cis-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yl)oxy}-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(cis-4-{N-[(N-methyl-N-2-methoxyethyl-amino)carbonyl]-piperidin-4-yl]oxy}-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(1-methylpiperidin-4-yl)-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(1-methanesulphonylpiperidin-4-yl)-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(1-methylpiperidin-4-yl)-7(2-methoxy-ethoxy)-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(1-acetyl-piperidin-4-yl)-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(1-ethyl-piperidin-4-yl)-7-methoxy-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(1-methyl-piperidin-4-yl)-7(2-methoxy-ethoxy)-quinazoline, 4-[3-chloro-4-fluorophenyl]amino]-6-(cis-4-{N-acetyl-N-methyl-
amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-[(N-[morpholin-4-yl]carbonyl]-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, and 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(2-methoxyethyl)carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline,

optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts, the solvates and/or hydrates thereof.

EGFR-inhibitors are preferably selected from among 4-[(3-chloro-4-fluorophenyl)amino]-6-{4-(morpholin-4-yl)-1-oxo-2-buten-1-yl amino }-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl amino ]-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[2-(2-(S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(5.5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl amino)]-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(2-methoxy-ethyl)-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(l-acetyl-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(l-methyl-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(l-methanesulphonyl-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(2-methoxyethyl)carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(N-(2-methoxy-ethyl)-N-methyl-amino)-1-oxo-2-buten-1-yl amino]-7-cyclopropylmethoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-[(4-(5.5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl amino)]-7-cyclopropylmethoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-[(2-methoxy-ethyl)-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-[(l-acetyl-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-[(l-methyl-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-[(l-methanesulphonyl-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-[(morpholin-4-yl)carbonyl]-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-[(2-methoxy-ethyl)-piperidin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(trans-4-methanesulphonyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[cis-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-
(trans-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(3-chloro-4-fluorophenyl)(N-methyl-amino)cyclohexan-1-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(N-[morpholin-4-yl]carbonyl)-N-methyl-amino]-cyclohexan-1-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-(2-(2,2-dimethyl-6-oxo-morpholin-4-yl)ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-(l-methanesulphonylpiperidin-4-yloxy)-7-methoxy-quinazoline and 4-[(3-chloro-4-fluorophenyl)amino]-6-(l-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts, the solvates and/or hydrates thereof.

By acid addition salts with pharmacologically acceptable acids which the EGFR-inhibitors may be capable of forming are meant, for example, salts selected from among the hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydrofumarate, hydrotartrate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate, preferably hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate.

Examples of dopamine agonists which may be used preferably include compounds selected from among bromocriptine, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexol, ropinirol, talipexol, terguride and viozan. Any reference to the above-mentioned dopamine agonists within the scope of the present invention includes a reference to any pharmacologically acceptable acid addition salts and optionally hydrates thereof which may exist. By the physiologically acceptable acid addition salts which may be formed by the above-mentioned dopamine agonists are meant, for example, pharmaceutically acceptable salts which are selected from the salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid and maleic acid.

Examples of HI-antihistamines preferably include compounds selected from among epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetinden, clemastine, bamipin, cexchlorpheniramine, pheniramine, doxylamine, chlorophenoxyamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclozine. Any reference to the above-mentioned HI-antihistamines within the scope of the present invention includes a reference to any pharmacologically acceptable acid addition salts which may exist.
Examples of PAF-antagonists preferably include compounds selected from among 4-(2-chlorophenyl)-9-methyl-2-[3(4-morpholiny1)-3-propanon-l-yl]-6H-thieno-[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepines, 6-(2-chlorophenyl)-8,9-dihydro-1-methyl-8-[(4-morpholiny1)carbonyl]-4H,7H-cyclo-penta-[4,5]thieno-[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines.

MRP4-inhibitors used are preferably compounds selected from among N-acetyl-dinitrophenyl-cysteine, cGMP, cholate, diclofenac, dehydroepiandrosterone 3-glucuronide, dehydroepiandrosterone 3-sulphate, dilazep, dinitrophenyl-s-glutathione, estradiol 17-β-gluconuronide, estradiol 3,17-disulphate, estradiol 3-glucuronide, estradiol 3-sulphate, estrene 3-sulphate, flurbiprofen, folate, N5-formyl-tetrahydrofolate, glycocholate, glycolithocholic acid sulphate, ibuprofen, indomethacin, indoprofen, ketoprofen, lithocholic acid sulphate, methotrexate, MK571 ((E)-3-[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-[3-dimethylamino]-3-oxopropyl]thio)[[methyl]thio]-propanoic acid), a-naphthyl -P-D-glucuronide, nitrobenzyl mercaptopurine riboside, probenecid, PSC833, sildenafil, sulfinpyrazone, taurochenodeoxycholate, taurocholate, taurodeoxycholate, taurolithocholate, taurolithocholic acid sulphate, topotecan, trequinsin and zaprinast, dipyridamole, optionally in the form of the racemates, enantiomers, diastereomers and the pharmacologically acceptable acid addition salts and hydrates thereof.

MRP4-inhibitors are preferably selected from among N-acetyl-dinitrophenyl-cysteine, dehydroepiandrosterone 3-sulphate, dilazep, dinitrophenyl-S-glutathione, estradiol 3,17-disulphate, flurbiprofen, glycocholate, glyco lithocholic acid sulphate, ibuprofen, indomethacin, indoprofen, lithocholic acid sulphate, MK571, PSC833, sildenafil, taurochenodeoxycholate, taurocholate, taurodeoxycholate, taurolithocholate, taurolithocholic acid sulphate, trequinsin and zaprinast, dipyridamole, optionally in the form of the racemates, enantiomers, diastereomers and the pharmacologically acceptable acid addition salts and hydrates thereof.

Particularly preferred MRP4-inhibitors are selected from among dehydroepiandrosterone 3-sulphate, estradiol 3,17-disulphate, flurbiprofen, indomethacin, indoprofen, MK571, taurocholate, optionally in the form of the racemates, enantiomers, diastereomers and the pharmacologically acceptable acid addition salts and hydrates thereof. The separation of enantiomers from the racemates can be carried out using methods known from the art (e.g. chromatography on chiral phases, etc.)

By acid addition salts with pharmacologically acceptable acids are meant, for example, salts selected from among the hydrochlorides, hydrobromides, hydroiodides, hydrosulphates, hydrophosphates, hydromethanesulphonates, hydronitrates, hydromaleates, hydroacetates,
hydrobenzoates, hydrocitrates, hydrofumarates, hydrotartrates, hydrooxalates, hydrosuccinates, hydrobenzoates and hydro-\textit{-/?}-toluenesulphonates, preferably the hydrochlorides, hydrobromides, hydrosulphates, hydrophosphates, hydrofumarates and hydromethanesulphonates.

The invention further relates to pharmaceutical preparations which contain a triple combination of the CCR2 inhibitors, MRP4-inhibitors and another active substance according to the invention, such as, for example, an anticholinergic, a steroid, an LTD4-antagonist or a betamimetic, and the preparation thereof and the use thereof for treating respiratory complaints.

carbamoyl]-methyl]-4-(2-imidazol-1-yl-pyrimidin-4-yl)-piperazin-1-carboxylate (BBS-2) (Drugs Future 2004, 29, 45-52), (R)-1-(2-imidazol-1-yl-6-methyl-pyrimidin-4-yl)-pyrrolidine-2-carboxylic acid (2-benzo[1.3]dioxol-5-yl-ethyl)-amide (BBS-2) (Drugs Future 2004, 29, 45-52) and the pharmaceutical salts, prodrugs or solvates thereof.

Compounds which may be used as SYK-inhibitors are preferably compounds selected from among: R343 or R788.

Examples of preferred MAP kinase inhibitors, as for example p38, ERK1, ERK2, JNK1, JNK2, JNK3 or SAP, which may be mentioned include SCIO-323, SX-01 1, SD-282, SD-169, NPC-037282, SX-004, VX-702, GSK-681323, GSK-856553, ARRY-614, ARRY-797, ARRY-438162, ARRY-p38-002, ARRY-371797, AS-602801, AS-601245, AS-602183, CEP-1347, KC706, TA-5493, RO-6226, Ro-1487, SC-409, CBS-3595, VGX-1027, PH-797804, BMS-582949, TA-5493 and BIRB-796 optionally in racemic form, as enantiomers, diastereomers or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred inhibitors of the NF-κB signalling pathway including IKK2 kinase inhibitors which may be mentioned include: MD-1041, MLN-041 und AVE-0547 optionally in racemic form, as enantiomers, diastereomers or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred Leukotriene biosynthesis inhibitors, as for example 5-Lipoxygenase (5-LO) inhibitors, cPLA2 inhibitors, Leukotriene A4 hydrolase inhibitors oder FLAP inhibitors, which may be mentioned include zileuton, tipelukast, licofelone, darapladib, TA-270, IDEA-033, IDEA-070, NIK-639, ABT-761, fenleuton, tepopaxilin, AM-103, AM-803, Abbott-79175, Abbott-85761, PLT-3514, CMI-903, PEP-03, CMI-977, MLN-977, CMI-947, LDP-977, efipladib, PLA-695, veliflapon, MK-591, MK-886 und BAYx1005 optionally in racemic form, as enantiomers, diastereomers or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred non-steroidal anti-inflammatory agents (NSAIDs) which may be mentioned include COX-2 inhibitors: propionic acid derivitives (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenhufen, fenoprofen, flubiprofen, ibuprofen, indoprofen, ketoprofen, miproprofen, naproxen, oxaprazin, pirprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivitives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclolafenac, fenclozic acid, fentiazac, furofenac, ibufenac, 1soxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivitives (meclofenamic acid, mafenamic acid, and tolfenamic acid), biphenyl- carboxylic acid derivitives, oxicams (isoxicam, meloxicam, piroxicam, sudoxicam and tenoxicam),
salicylates (acetyl salicylic acid, sulfasalazine) and the pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone, phenylbutazone), and the coxibs (celecoxib, valecoxib, rofecoxib and etoricoxib) optionally in racemic form, as enantiomers, diastereomeres or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred CCR1 antagonists which may be mentioned include AZD-4818, CCX-354, MLN-3701, MLN-3897, optionally in racemic form, as enantiomers, diastereomeres or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred CCR5 antagonists which may be mentioned include maraviroc, INCB-15050, CCR5mAb004, GSK-706769, PRO-140, SCH-532706, vicriviroc and nifeviroc optionally in racemic form, as enantiomers, diastereomeres or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred CXCR1 or CXCR2 antagonists which may be mentioned include SCH-527123 and SB-656933 optionally in racemic form, as enantiomers, diastereomeres or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred Neurokinin (NK1 or NK2) antagonists which may be mentioned include Saredutant, Nepadutant, PRX-96026 und Figopitant optionally in racemic form, as enantiomers, diastereomeres or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred purinergic receptor modulators, including P2X7 inhibitors, which may be mentioned include AZD-9056 optionally in racemic form, as enantiomers, diastereomeres or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred PPAR gamma modulators which may be mentioned include Rosiglitazone, Ciglitazone, Pioglitazone and SMP-028 optionally in racemic form, as enantiomers, diastereomeres or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred Interleukin 1-beta converting enzyme (ICE) inhibitors which may be mentioned include Pralnacasan, VRT-18858, RU-36384, VX-765 and VRT-43198 optionally in racemic form, as enantiomers, diastereomeres or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred Toll-like receptor (TLR) modulators which may be mentioned include Resiquimod, PF-35 12676, AVE-0675, Heplisav, IMO-2055, CpG-28, TAK-242, SAR-21609, RC-52743198 and 852A optionally in racemic form, as enantiomers, diastereomeres or as pharmacologically acceptable salts, solvates or hydrates.
Examples of preferred VLA4 antagonists which may be mentioned include Natalizumab, Valategrast, TBC-4746, CDP-323 and TL-1 102 optionally in racemic form, as enantiomers, diastereomers or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred ICAM-1 inhibitors which may be mentioned include BIRT-2584 optionally in racemic form, as enantiomers, diastereomers or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred anti-TNF antibodies which may be mentioned include Infliximab, Adalimumab, Golimumab. CytoFab and Etanercept.

Examples of preferred mucoregulators which may be mentioned include MSI-2216, Erdosteine, Fluorovent, Talniflumate, INO-4995, BIO-11006, VR-496 and fudosteine optionally in racemic form, as enantiomers, diastereomers or as pharmacologically acceptable salts, solvates or hydrates.

Examples of preferred Antiviral drugs which may be mentioned include acyclovir, tenovir, pleconaril, peramivir, pocosanol.

Examples of preferred Antibiotic drugs like gentamicin, streptomycin, geldanamycin, doripenem, cephalexin, cefaclor, ceftazidine, cefepime, erythromycin, vancomycin, aztreonam, amoxicillin, bacitracin, enoxacin, mafenide, doxycycline, chloramphenicol.

Examples of preferred opiate receptor agonists are selected from among morphine, propoxyphene (Darvon), tramadol, buprenorphin.

Examples of preferred anti-TNF antibodies or TNF-receptor antagonists such as but not limited to Etanercept, Infliximab, Adalimumab (D2E7), CDP 571, and Ro 45-2081 (Lenercept), or biologic agents directed against targets such as but not limited to CD-4, CTLA-4, LFA-1, IL-6, ICAM-1, C5 and Natalizumab.

Examples of preferred IL-1 receptor antagonists such as but not limited to Kineret; Sodium channel blockers: carbamazepine, mexiletine, lamotrigine, tectin, lacosamide

Examples of preferred N-type calcium channel blockers are selected from among Ziconotide.

Examples of preferred Serotonergic and noradrenergic modulators such as but not limited to paroxetine, duloxetine, clonidine, amitriptyline, citalopram;
Examples of preferred Histamine H1 receptor antagonists such as but not limited to bromopheniramine, chlorpheniramine, dexchlorpheniramine, tripolidine, clemastine, diphenhydramine, diphenylpyraline, tripelemnamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, cetirizine, desloratadine, fexofenadine and levocetirizine.

Examples of preferred Histamine H2 receptor antagonists such as but not limited to cimetidine, famotidine and ranitidine.

Examples of preferred proton pump inhibitors such as but not limited to omeprazole, pantoprazole and esomeprazole.

Examples of preferred Leukotriene antagonists and 5-lipoxygenase inhibitors such as but not limited to zafirlukast, montelukast, pranlukast and zileuton.

Examples of preferred local anesthetics such as but not limited to ambroxol, lidocaine.

Examples of preferred potassium channel modulators such as but not limited to retigabine.

Examples of preferred GABA modulators such as but not limited to lacosamide, pregabalin, gabapentin.

Examples of preferred anti-migraine drugs such as but not limited to sumatriptan, zolmitriptan, naratriptan, eletriptan, telcegepant.

Examples of preferred NGF antibodies such as but not limited to RI-724.

Combination therapy is also possible with new principles for the treatment of pain e.g. P2X3 antagonists, VR1 antagonists, NK1 and NK2 antagonists, NMDA antagonists, mGluR antagonists and the like.

**Pharmaceutical formulations**

Suitable forms for administration are for example tablets, capsules, solutions, syrups, emulsions or inhalable powders or aerosols. The content of the pharmaceutically effective compound(s) in each case should be in the range from 0.1 to 90 wt.%, preferably 0.5 to 50 wt.% of the total composition, i.e. in amounts which are sufficient to achieve the dosage range specified hereinafter.
The preparations may be administered orally in the form of a tablet, as a powder, as a powder in a capsule (e.g. a hard gelatine capsule), as a solution or suspension. When administered by inhalation the active substance combination may be given as a powder, as an aqueous or aqueous-ethanolic solution or using a propellant gas formulation.

Preferably, therefore, pharmaceutical formulations are characterised in that they contain one or more compounds of formula (I) according to the preferred embodiments above.

It is particularly preferable if the compounds of formula (I) are administered orally, and it is also particularly preferable if they are administered once or twice a day. Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.

Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidine or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.

Syrups containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as 2-hydroxybenzoates.

Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.

Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).

For oral administration the tablets may, of course, contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like. Moreover, lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tabletting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.

It is also preferred if the compounds of formula (I) are administered by inhalation, particularly preferably if they are administered once or twice a day. For this purpose, the compounds of formula (I) have to be made available in forms suitable for inhalation. Inhalable preparations include inhalable powders, propellant-containing metered-dose aerosols or propellant-free inhalable solutions, which are optionally present in admixture with conventional physiologically acceptable excipients.

Within the scope of the present invention, the term propellant-free inhalable solutions also includes concentrates or sterile ready-to-use inhalable solutions. The preparations which may be used according to the invention are described in more detail in the next part of the specification.

**Inhalable powders**

If the active substances of formula (I) are present in admixture with physiologically acceptable excipients, the following physiologically acceptable excipients may be used to prepare the inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextran), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these excipients with one another. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
Methods of preparing the inhalable powders according to the invention by grinding and micronising and by finally mixing the components together are known from the prior art.

**Propellant-containing inhalable aerosols**

The propellant-containing inhalable aerosols which may be used according to the invention may contain the active substances of formula (I) dissolved in the propellant gas or in dispersed form. The propellant gases which may be used to prepare the inhalation aerosols according to the invention are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as preferably fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The propellant gases mentioned above may be used on their own or in mixtures thereof. Particularly preferred propellant gases are fluorinated alkane derivatives selected from TG134a (1,1,1,2-tetrafluoroethane), TG227 (1,1,1,2,3,3,3-heptafluoropropane) and mixtures thereof. The propellant-driven inhalation aerosols used within the scope of the use according to the invention may also contain other ingredients such as co-solvents, stabilisers, surfactants, antioxidants, lubricants and pH adjusters. All these ingredients are known in the art.

**Propellant-free inhalable solutions**

The compounds of formula (I) according to the invention are preferably used to prepare propellant-free inhalable solutions and inhalable suspensions. Solvents used for this purpose include aqueous or alcoholic, preferably ethanolic solutions. The solvent may be water on its own or a mixture of water and ethanol. The solutions or suspensions are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from inorganic or organic acids. Examples of particularly suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid. Examples of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc. Preferred inorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which have already formed an acid addition salt with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the above acids may also be used, particularly in the case of acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example. According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH. Co-solvents and/or other excipients may be added to the propellant-free inhalable solutions used for the purpose according to the invention. Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols - particularly isopropyl alcohol, glycols - particularly propylene glycol, polyethylene glycol, polypropylene glycol, glycolether,
glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters. The terms excipients and additives in this context denote any pharmacologically acceptable substance which is not an active substance but which can be formulated with the active substance or substances in the pharmacologically suitable solvent in order to improve the qualitative properties of the active substance formulation. Preferably, these substances have no pharmacological effect or, in connection with the desired therapy, no appreciable or at least no undesirable pharmacological effect. The excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art. The additives also include pharmacologically acceptable salts such as sodium chloride as isotonic agents. The preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins or provitamins occurring in the human body. Preservatives may be used to protect the formulation from contamination with pathogens. Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art. For the treatment forms described above, ready-to-use packs of a medicament for the treatment of respiratory complaints are provided, containing an enclosed description including for example the words respiratory disease, COPD or asthma, a pteridine and one or more combination partners selected from those described above.

25 Experimental procedures and synthetic examples

LIST of ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>acetonitrile</td>
</tr>
<tr>
<td>APCI</td>
<td>atmospheric pressure chemical ionization (in MS)</td>
</tr>
<tr>
<td>Ctrl</td>
<td>control</td>
</tr>
<tr>
<td>DAD</td>
<td>diode array detector</td>
</tr>
<tr>
<td>DMA</td>
<td>N,N-dimethylacetamide</td>
</tr>
<tr>
<td>DMF</td>
<td>N,N-dimethylformamide</td>
</tr>
<tr>
<td>DMSO</td>
<td>dimethyl sulfoxide</td>
</tr>
<tr>
<td>EI</td>
<td>electron impact (in MS)</td>
</tr>
<tr>
<td>ESI</td>
<td>electrospray ionization (in MS)</td>
</tr>
<tr>
<td>ex</td>
<td>example</td>
</tr>
<tr>
<td>GC/MS</td>
<td>gas chromatography with mass spectrometric detection</td>
</tr>
<tr>
<td>h</td>
<td>hour(s)</td>
</tr>
</tbody>
</table>
HATU: 0-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate

HPLC: high performance liquid chromatography

HPLC/MS: coupled high performance liquid chromatography-mass spectrometry

5 min: minutes

MS: mass spectrometry

NMP: N-Methyl-2-pyrrolidinone

NMR: nuclear magnetic resonance

R_t: retention time (in HPLC)

10 sec: secondary

TBTU: 0-(1H-benzo-1,2,3-triazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate

tert: tertiary

TFA: trifluoroacetic acid

15 THF: tetrahydrofurane

TLC: thin-layer chromatography

UV: ultraviolet absorption

20 ANALYTICAL METHODS

HPLC methods

Methods:

- 2Ca

Column: MERCK; Chromolith Flash; RP18e; 25x4.6 mm

Mobile phase:

A = water + 0.1% HCOOH;  B = ACN + 0.1% HCOOH

Flow rate: 1.6 ml/min

Gradient:

<table>
<thead>
<tr>
<th>A %</th>
<th>B %</th>
<th>Time [min]</th>
</tr>
</thead>
<tbody>
<tr>
<td>90</td>
<td>10</td>
<td>0.00</td>
</tr>
<tr>
<td>10</td>
<td>90</td>
<td>2.70</td>
</tr>
<tr>
<td>10</td>
<td>90</td>
<td>3.00</td>
</tr>
<tr>
<td>90</td>
<td>10</td>
<td>3.30</td>
</tr>
</tbody>
</table>

Equipment

Instrument: Agilent Technology; HP 1100 Series, DAD

Detection: UV 190 - 400 nm

Detection: Agilent Technology; HP 1100 MSD

Ion source: ESI +
Methods:

• **2Cc**
  - Column: MERCK; Chromolith Flash; RP18e; 25x4.6 mm, at 60°C
  - Mobile: A = water + 0,1% HCOOH; B = MeOH
  - Flow rate: 2.5 ml/min
  - Gradient:
    - A %  B %  Time [min]
    - 90 10 0.00
    - 0 100 1.61
    - 0 100 2.25

Equipment

- Instrument: Agilent Technology; HP 1200 Series, DAD
- Detection: UV 190 - 400 nm
- Ion source: ESI +

Methods:

• **21 (isocratic)**
  - Column: DAICEL AS-H 5 µm, 4.6x250 mm
  - Mobile phase: A = Hexane; B = EtOH (con AS-H), IPA (con AD-H)
    - A/B = 98/2%
  - Flow rate: 1 ml/min

• **21a (isocratic)**
  - Column: DAICEL Chiralpack AS-H 5 µm, 4.6x250 mm
  - Mobile phase: A = Hexane; B = EtOH
    - A/B = 98/2%
  - Flow rate: 1 ml/min

• **2Ja (isocratic)**
  - Column: DAICEL Chiralpack AD-H 5 µm, 4.6x250 mm
  - Mobile phase: A = Hexane; B = Isopropanol
    - A/B = 80/20%
  - Flow rate: 1 ml/min

• **2Ka (isocratic)**
  - Column: DAICEL Chiralcel OJ-H 5 µm, 4.6x250 mm
  - Mobile phase: A = Hexane; B = EtOH
A/B = 98/2%

Flow rate: 1 ml/min

**Equipment**

| Instrument | LC Agilent Technologies. HPLC 1100 Serie, DAD Version A. |
| Detection  | UV 220 - 300nm |

**Methods:**

- **Y1 1**
  
  | Column:      | Waters; XBridge C18, 4.6 x 30 mm, 3.5 μη, at 60°C |
  | Mobile:      | A = water + 0.1% TFA; B = MeOH + 0.1% TFA |
  | Gradient:    | A % B % Time [min] Flow rate [ml/min] |
  |             | 95  5  0.00  4 |
  |             | 95  5  0.15  4 |
  |             | 0  100 1.70  4 |
  |             | 0  100 2.25  4 |

- **Y8 1**
  
  | Column:      | Waters; Sunfire C18, 4.6 x 30 mm, 3.5 μη, at 60°C |
  | Mobile:      | A = water + 0.1% HCOOH; B = MeOH |
  | Gradient:    | A % B % Time [min] Flow rate [ml/min] |
  |             | 95  5  0.00  4 |
  |             | 95  5  0.15  4 |
  |             | 0  100 1.70  4 |
  |             | 0  100 2.25  4 |

**Equipment:**

| Instrument | Agilent Technology; 1100 Series, DAD |
| Detection  | UV 210 - 400 nm |
| Detection  | Agilent Technology; 1100 MSD |
| Ion source | ESI + |

**Method:**

- **Z1 2**
  
  | Column:      | Waters; XBridge C18, 3 x 30 mm, 2.5 μη, at 60°C |
  | Mobile:      | A = water + 0.2% TFA; B = MeOH |
  | Gradient:    | A % B % Time [min] Flow rate [ml/min] |
  |             | 95  5  0.00  2.2 |
  |             | 95  5  0.05  2.2 |
  |             | 0  100 1.40  2.2 |
Equipment:
Instrument: Agilent Technology; 1200 Series, DAD
Detection: UV 210 - 400 nm
Detection: Agilent Technology; 1200 MSD
Ion source: ESI +

**GC-MS methods:**

Methods:
- **3A**
  - Column: Agilent DB-5MS, 25m x 0.25mm x 0.25 µm
  - Carrier gas: Helium, 1 ml/min constant flow
  - Oven Program: 50°C (hold 1 min.), to 100°C in 10°C / min, to 200°C in 20°C / min, to 300°C in 30°C / min

- **3B**
  - Column: Agilent DB-5MS, 25m x 0.25mm x 0.25 µm
  - Carrier gas: Helium, 1 ml/min constant flow
  - Oven Program: 80°C to 110°C in 10°C / min (hold 40 min), to 280°C in 30°C / min

**Synthesised**

**Intermediate 1**

Commercially available (R)-3-phenylcyclohexanone (2.0 g, 11.48 mmol) and 1-isocyanomethanesulfonyl-4-methyl-benzene (2.91g, 14.92 mmol) in 10 ml of 1,2-dimethoxyethane were stirred at 0°C. A solution of potassium tert-butoxide (2.57 g, 22.96 mmol) in 10 ml 1,2-dimethoxyethane and 20 ml tert-butanol was added dropwise and the
reaction mixture was allowed to reach room temperature and stirred overnight. The reaction mixture was diluted with diethyl ether and washed with ice water. The organic phase was separated, washed with brine, dried over sodium sulfate and concentrated under vacuum. 2.1 g (11.2 mmol) of the desired product were obtained.

5 GC/MS (method 3A) Rᵣ = 11.52 min and 11.68 min (diastereoisomeric mixture) [M]⁺ = 185

**Intermediate 2**

![Intermediate 2](image)

Intermediate 1 (2.1 g, 11.2 mmol) was stirred under reflux in 20 ml of 96% sulfuric acid and 20 ml water overnight. The reaction mixture was cooled, treated with a 30% aqueous solution of sodium hydroxide and ice and washed with dichloromethane. The basic water phase was treated with 37% aqueous solution of hydrochloric acid. The acidic aqueous solution was extracted with dichloromethane. The organic phase was washed with brine, dried over sodium sulfate and concentrated under vacuum. 1.85 g (9.1 mmol) of the desired compound were obtained as a diastereoisomeric mixture and used in the next steps without further purification.

**Intermediate 3a**

![Intermediate 3a](image)

Intermediate 2 (1.85 g, 9.06 mmol, mixture of 2 diastereomers) and triethylamine (2.02 ml, 14 mmol) were stirred at 0°C in 10 ml tetrahydrofuran. A solution of ethylchloroformate (1.29 ml, 13.58 mmol) in 5 ml tetrahydrofuran was added dropwise and the reaction mixture was stirred at 0°C for 1 h. Then, 10 ml of a 30% aqueous solution of ammonium hydroxide were added dropwise and the reaction mixture was allowed to reach room temperature and stirred overnight. The reaction mixture was concentrated under vacuum, dissolved with dichloromethane, washed with a 1M aqueous solution of sodium hydroxide, washed with brine, dried over sodium sulfate and concentrated under vacuum. The crude product was purified by flash chromatography (Isolute silica cartridge 70 g; eluent: dichloromethane/methanol=99/1%). 145 mg (0.71 mmol) of diastereoisomERICALLY pure
(IR,3R)-3-phenyl-cyclohexanecarboxylic acid amide (relative stereochemistry assigned by NMR) were obtained.

GC/MS (method 3A) \( R_t = 12.88 \) min \( [M]^+ = 203 \)

**Intermediate 3b**

Further elution of the column gave 230 mg (1.13 mmol) of the diastereoisomerically pure (IS,3R)-3-phenyl-cyclohexanecarboxylic acid amide (relative stereochemistry assigned by NMR).

GC/MS (method 3A) \( R_t = 13.03 \) min \( [M]^+ = 203 \)

**Intermediate 4**

4.53 ml of a 1M solution of lithium aluminium hydride (4.53 mmol) in tetrahydrofuran was dissolved in 30 ml tetrahydrofuran and stirred at 0°C under nitrogen atmosphere. Intermediate 3b (230 mg, 1.13 mmol) in 10 ml tetrahydrofuran was added dropwise. The reaction mixture was stirred at 0°C for 2h and then quenched with water and ice. The reaction mixture was extracted with dichloromethane. The organic phase was washed with a 1M aqueous solution of sodium hydroxide, brine, dried over sodium sulfate and concentrated under vacuum. 180 mg (0.95 mmol) of the desired product were obtained.

GC/MS (method 3A) \( R_t = 11.47 \) min \( [M]^+ = 189 \)

**Intermediate 5a**

To a solution of lithium bromide (24 g, 277.1 mmol) in 500 ml of dry tetrahydrofuran, stirred under nitrogen atmosphere, copper(I) bromide (19.87 g, 138.5 mmol) was added. The
reaction mixture was stirred at room temperature until a solution was obtained. Then, the reaction mixture was cooled to 0°C and a 0.5M solution of commercially available 4-tolyl magnesium bromide in THF (277.1 ml, 138.5 mmol) was added. Then, commercially available 4-chlorocarbonyl-butyric acid ethyl ester (19 g, 115.4 mmol) was added and the reaction mixture was stirred at 0°C for 18 h.

500 ml of a saturated aqueous ammonium chloride solution was added and the reaction mixture was extracted twice with dichloromethane. The organic phase was washed with a saturated aqueous sodium bicarbonate solution, dried over sodium sulfate and concentrated under vacuum. The crude product (20 g) was used in the next step without any purification.

**Intermediate 6a**

![Intermediate 6a](image)

To a solution of intermediate 5a (20 g, 90.8 mmol) in 50 ml of tetrahydrofuran 50 ml of water and lithium hydroxide monohydrate (11.43 g, 274.40 mmol) were added and the reaction mixture was stirred at 50°C for 1 h. The reaction mixture was extracted with ethyl acetate and the layers were separated. The aqueous layer was acidified with aqueous HCl (37%) until pH 1 and then extracted with dichloromethane. The organic layer was dried over sodium sulfate and concentrated under vacuum. The crude product was triturated with diisopropyl ether. The solvent was removed by filtration yielding the desired product (13 g, 63.1 mmol).

**Intermediate 7a**

![Intermediate 7a](image)

A suspension of intermediate 6a (11.5 g, 55.8 mmol) in 250 ml water was cooled to 10°C. Then, potassium hydroxide (7.82 g, 139.4 mmol) and sodium borohydride (1.83 g, 48.5 mmol) were added and the reaction mixture was allowed to reach room temperature and stirred for 2 h. 13 ml of a 12M aqueous hydrochloric acid was added and the reaction mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under vacuum to give the crude product (11 g, 52.8 mmol).

The following intermediates were synthesized in analogy to Intermediates 5a, 6a and 7a.
Intermediate 8a

Intermediate 7a (6 g, 28.8 mmol) was dissolved in 100 ml of dichloromethane. 1.5 ml trifluoro acetic acid were added and the reaction mixture was stirred at room temperature for 18h. The reaction mixture was diluted with 50 ml of dichloromethane and washed with 50 ml of a saturated aqueous sodium bicarbonate solution and water. The organic layer was dried over sodium sulfate and removed under vacuum to give the desired product (4.38 g, 23.0 mmol).
Intermediate 9a

A solution of intermediate 8a (4.38 g, 23.0 mmol) in 110 ml of dichloromethane was cooled to -78°C. Then, a 1M solution of diisobutylaluminiumhydride (46.15 ml, 46.15 mmol) in dichloromethane was added dropwise. The reaction mixture was stirred at -78°C for 2 h. 100 ml of methanol were added at -78°C and the reaction mixture was allowed to reach room temperature. The reaction mixture was concentrated under vacuum and the crude product obtained was triturated with ethyl ether. The precipitate was filtered off and washed with diethyl ether. The organic layer was removed under vacuum to give the crude lactol (4.4g, 22.9 mmol). The lactol was dissolved in 80 ml of dry dichloromethane and cooled to 0°C. Then, triethylamine (4.96 ml, 34.3 mmol), acetic anhydride (2.54 ml, 27.5 mmol) and 4-dimethylaminopyridine (279.6 mg, 2.3 mmol) were added. The reaction mixture was allowed to reach room temperature and stirred for lh. A saturated aqueous sodium bicarbonate solution was added and the mixture was extracted with dichloromethane. The organic phase was dried over sodium sulfate and concentrated under vacuum. The residue was purified by flash chromatography (Biotage SP1 cartridge 50g, eluent: cyclohexane/ethyl acetate=95/5) to give the desired product (4 g, 17.1 mmol).

The following intermediates were synthesized in analogy to Intermediates 8a and 9a.

<table>
<thead>
<tr>
<th>Starting Hydroxy-acid Intermediate</th>
<th>Lactone Intermediate</th>
<th>STRUCTURE</th>
<th>Lactol-acetate Intermediate</th>
<th>STRUCTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7b</td>
<td>8b</td>
<td><img src="image" alt="Structure" /></td>
<td>9b</td>
<td><img src="image" alt="Structure" /></td>
</tr>
</tbody>
</table>

73
Intermediate 10a

Trimethylsilylcyanide (0.52 ml, 4.16 mmol) and borontrifluoride etherate (0.27 ml, 2.2 mmol) were added to a solution of intermediate 9a (650 mg, 2.77 mmol) in 50 ml of acetonitrile under nitrogen atmosphere at room temperature. The reaction mixture was stirred for 18h. The reaction mixture was concentrated under vacuum to give the desired product (mixture of diastereoisomers).

GC/MS (method 3A) $R_t = 10.47$ min and 10.68 min (diastereoisomeric mixture, ratio trans/cis = 8/2)

Intermediate 11a

Intermediate 10a was purified by flash chromatography (Biotage Sp1 cartridge 25g, eluent: cyclohexane/ethyl acetate=99/1). 400 mg of diastereomerically pure trans stereoisomer was obtained (racemate, relative configuration assigned by NMR).

GC/MS (method 3A) $R_t = 10.47$ min

Intermediate 12a

Further elution of the column gave 100 mg of the diastereomerically pure cis stereoisomer (racemate, relative configuration assigned by NMR).

GC/MS (method 3A) $R_t = 10.68$ min
Intermediate 12a was also obtained by epimerization of Intermediate 11a: Intermediate 11a (3.2 g, 15 mmol) was dissolved in 40 ml of tetrahydroiurane. Potassium tert-butoxide (178 mg, 1 mmol) was added and the reaction mixture was stirred at room temperature for 0.5h. The solid was removed by filtration and the reaction mixture was concentrated under vacuum. The crude product was purified by flash chromatography (Biotage SP1 cartridge 50g, eluent: cyclohexane/ethyl acetate=99/1). 1.45 g of the desired cis diastereoisomer were obtained.

The following intermediates were synthesized in analogy to Intermediates 10a, 11a and 12a.

<table>
<thead>
<tr>
<th>Starting Lactol-acetate Intermediate</th>
<th>STRUCTURE</th>
<th>Intermediate</th>
<th>STRUCTURE</th>
<th>Intermediate</th>
<th>STRUCTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9b</td>
<td><img src="image1.png" alt="9b Diagram" /></td>
<td>10b</td>
<td><img src="image2.png" alt="10b Diagram" /></td>
<td>11b</td>
<td><img src="image3.png" alt="11b Diagram" /></td>
</tr>
<tr>
<td>9c</td>
<td><img src="image5.png" alt="9c Diagram" /></td>
<td>10c</td>
<td><img src="image6.png" alt="10c Diagram" /></td>
<td>11c</td>
<td><img src="image7.png" alt="11c Diagram" /></td>
</tr>
</tbody>
</table>
**Intermediate 13a**

Racemic Intermediate 12a (1.17 g, 2.06 mmol) was separated by chiral HPLC (semi-preparative column). 400 mg (2.0 mmol) were obtained as single enantiomer.

Chiral HPLC (method 21 isocratic): \( R_t = 8.74 \) min

**Intermediate 14a**

Further elution of the column gave 390 mg (1.94 mmol) of the corresponding single enantiomer.

Chiral HPLC (method 21 isocratic): \( R_t = 9.06 \) min

Absolute stereochemistry was determined by X-ray crystallography:

Absolute stereochemistry was derived from the refinement of anomalous dispersion data. While an unambiguous assignment is not possible due to the lack of heavy atoms, the Flack parameter gave a clear tendency toward the indicated chiral configuration.

Crystal Data: \( C_i \) 3, His Ni Oi \( M_r = 201.26 \), orthorhombic, P2i2i2i, \( a = 8.0519(16) \AA \), \( b=1.185(2) \AA \), \( c=12.637(3) \AA \), \( V = 1138.2(4) \AA^3 \), \( Z = 4 \), \( D_x = 1.175 \text{g/cm}^3 \), \( 1 = 1.542 \text{A} \). m = 0.58mm\(^{-1} \), \( F(000) = 423 \), T = 100(1) K. Data Collection: 12235 measured reflections, 1888/130 unique, \( R_{int} = 0.079 \). Refinement: 138 parameters; hydrogen atoms were included as riding atoms, \( S = 1.02 \), \( R_1 = 0.052 \) for 1393 reflections with \( F_o > 4 \sigma(F_o) \). \( wR = 0.128 \) (Weight \( w = 1/\sigma^2(F_o) + (0.0864P)^2 + 0.0P \) where \( P = (F_o^2 + 2F_c^2)/3 \), largest difference peak: 0.31 \( e/\text{A}^3 \); largest difference hole -0.22 \( e/\text{A}^3 \), Flack= 0.2(5).

The following intermediates were separated in analogy to Intermediates 13a and 14a.
Absolute stereochemistry for intermediate 13b was derived from the refinement of anomalous dispersion data. While an unambiguous assignment is not possible due to the lack of heavy atoms, the Flack parameter gave a clear tendency toward the indicated chiral configuration.

Crystal Data: C12H12N3O3, M = 255.24, orthorhombic, P212121, a = 7.5726(15) Å, b = 11.053(2) Å, c = 14.173(3) Å, V = 11863.4 Å³, Z = 4, D = 1.429 g/cm³, μ = 1.542 mm⁻¹, F(000) = 528, T = 100(1) K. Data Collection: 8980 measured reflections, 1900/131 unique, Rint = 0.045. Refinement: 164 parameters; hydrogen atoms were included as riding atoms, S = 1.10, R = 0.065 for 1710 reflections with Fo > 4σ(Fo), wR = 0.167 (Weight = w/[σ²(Fo)² + (0.147 P)² + 1.0917P] where P = (Fo² + 2Fc) / 3), largest difference peak: 0.43 e/Å³, largest difference hole -0.39 e/Å³; Flack = 0.2(3).
Intermediate 15a

Intermediate 10a was dissolved in 20 ml of tetrahydrofurane, a 1M solution of borane-tetrahydrofurane complex (3.28 ml, 3.28 mmol) was added and the reaction mixture was stirred at room temperature for 18h. 20 ml of a saturated aqueous sodium bicarbonate solution and 50 ml of dichloromethane were added. The organic layer was dried over magnesium sulfate and concentrated under vacuum. 90 mg (0.44 mmol) of the desired product were obtained.

Intermediate 16a

was synthesized in analogy to Intermediate 15a starting from intermediate 12a.

Intermediate 17a

was synthesized in analogy to Intermediate 15a starting from intermediate 13a (absolute stereochemistry as shown).

Intermediate 18a

was synthesized in analogy to intermediate 15a starting from intermediate 14a (absolute stereochemistry as shown).

The following intermediates were synthesized in analogy to Intermediates 17a, 18a.
Intermediate 19a

N-methyl-N-piperidin-4-yl-methanesulfonamide hydrochloride (11 g, 47.91 mmol; WO2009/47161) was suspended in 200 ml of 1,2-dichloroethane, N,N-diisopropylethylamine (17.12 ml, 96.17 mmol) and commercially available L-(tert-butoxycarbonyl)-piperidin-4-one (9.58 g, 48.08 mmol) were added and the reaction mixture was stirred at room temperature for 30 min. Sodium triacetoxyborohydride (12.23 g, 57.50 mmol) was added and the reaction mixture was stirred at room temperature for 72h. The reaction mixture was diluted with dichloromethane and washed with an aqueous saturated sodium bicarbonate solution. The organic phase was dried over sodium sulfate and concentrated under vacuum. The crude product was purified by flash chromatography (Biotage SP1; silica gel cartridge: 65i; eluent: ethyl acetate/methanol 1:50/50%) to obtain 7.2 g (19.2 mmol) of the desired compound.
Intermediate 20a

Intermediate 19a (7.2 g, 19.2 mmol) was suspended in 20 ml of 1,4-dioxane, a 4M solution of hydrochloric acid (48 ml, 192 mmol) in 1,4-dioxane was added dropwise. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under vacuum. 6.3 g (18 mmol) of the desired compound were obtained.

The following intermediates were synthesized in analogy to Intermediates 19a and 20a.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1-(t-butylxycarbonyl)-4-oxopiperidine</td>
<td>commercially available</td>
<td>22b</td>
<td>-</td>
<td>19b</td>
<td></td>
<td>20b</td>
<td></td>
</tr>
</tbody>
</table>
Intermediate 21b

3-Methoxy-tetrahydro-pyran-4-one* (1 g, 7.68 mmol), commercially available (R)-(+)l-phenylethylamine (0.99 ml, 7.68 mmol) and Raney-Nickel (200 mg) in 10 ml of dry ethanol.
were stirred under a hydrogen atmosphere (5 bar) for 15 days. The reaction mixture was
diluted with 20 ml of methanol and 20 ml of tetrahydrofuran, stirred for 15 minutes, filtered
on a celite pad and concentrated under vacuum. The crude product was loaded on a SCX
cartridge (50g). The cartridge was washed with methanol and the desired product was eluted
with a 7 M solution of ammonia in methanol. The basic organic phase was concentrated under
vacuum and the crude product was purified by flash chromatography
dichloromethane/methanol = 98/2% to obtain 710 mg (3.02 mmol) of the desired product as
single stereoisomer (diastereoisomeric purity confirmed and relative cis configuration
assigned by NMR).

GC/MS (method 3B) $R_t = 35.04$ min

**Intermediate 21c**

was synthesised in analogy to Intermediate 21b, starting from 3-Methoxy-tetrahydro-pyran-4-
one and commercially available (S)-(-)-l-phenylethylamine (diastereoisomeric purity
confirmed and relative cis configuration assigned by NMR).

GC/MS (method 3B) $R_t = 35.04$ min

**Intermediate 22b**

Intermediate 21b (1.18 g, 5.01 mmol), Pd/C 10% (200 mg) and acetic acid (0.3 ml, 5.01
mmol) in 20 ml of methanol were stirred under a hydrogen atmosphere (5 bar) for 18h. The
reaction mixture was diluted with 20 ml of methanol, stirred for 15 minutes, filtered on a
celite pad and concentrated under vacuum. The crude product was loaded on a SCX
cartridge (50g). The cartridge was wash with methanol and the desired product was eluted with a 7 M
solution of ammonia in methanol. The basic organic phase was concentrated under vacuum
and 513 mg (3.91 mmol) of the desired product were obtained as single stereoisomer
Intermediate 22c

was synthesised in analogy to Intermediate 22b, starting from Intermediate 21c

Intermediate 23

A mixture of 5-bromo-4-methyl-3,6 (1H,2H)-pyridazinedione (500 mg, 2.4 mmol; Organic & Biomolecular Chemistry 2004, 1782-1788) and phosphorus oxychloride (3 ml) was refluxed for 1 h. The reaction mixture was poured onto ice water, extracted with dichloromethane, dried over sodium sulfate and concentrated in vacuum to give the crude product (407 mg, 2.1 mmol).

Intermediate 24a

A mixture of the crude intermediate 23 (400 mg, 2.0 mmol), 4-tert-butyl-benzylamine (321 µl, 2.0 mmol) and N,N-diisopropylethylamine (348 µl, 2.0 mmol) in 10 ml ethanol was heated to 70°C for 48 h. The mixture was cooled to room temperature and then directly purified by reversed phase HPLC to give the desired product (230 mg, 525 µmol).

Intermediate 25a

Sodium methylate (30%, 107 µl, 577 µmol) was added to a solution of intermediate 24a (230 mg, 525 µmol) in 3 ml methanol and heated in the microwave at 120°C for 1 h. The crude mixture was directly purified by reversed phase HPLC to give the desired product (154 mg, 355 µmol).
Intermediate 26a

A mixture of intermediate 25a (154 mg, 355 µmol), palladium acetate (8 mg, 35 µmol), 1,1'-bis(diphenylphosphino)-ferrocene (20 mg, 35 µmol), sodium acetate (87 mg, 1.1 mmol) in 5 ml methanol and 5 ml DMF was stirred under a carbon monoxide atmosphere (5 bar) for 48 h at 70°C. The mixture was filtered and concentrated in vacuum. The residue was purified by reversed phase HPLC to give the corresponding ester (53 mg, 154 µmol).

A 1 M aqueous solution of sodium hydroxide (386 µl) was added to a solution of the ester (53 mg, 154 µmol) in 3 ml methanol. The reaction mixture was stirred for 2 h at room temperature. The reaction mixture was acidified with trifluoroacetic acid and directly purified by reversed phase HPLC to give the desired product (48 mg, 108 µmol).

The following intermediates were synthesized in analogy to intermediates 24a, 25a and 26a starting from intermediate 23:

<table>
<thead>
<tr>
<th>Starting amine</th>
<th>di-Cl-pyridazine intermediate</th>
<th>STRUCTURE</th>
<th>24b</th>
<th>25b</th>
<th>26b</th>
<th>as shown</th>
<th>Stereochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The following synthesis sequence allows the preparation of Intermediates 17b, 17c, 18a:

**Intermediate 27a**

To a solution of commercially available 4-(trifluoromethyl)-benzoyl chloride (25 g, 112 mmol) in 250 ml dry tetrahydrofuran under nitrogen atmosphere, dimethylamine dihydrochloride (14.7 g, 180 mmol) and potassium carbonate (49.62 g, 360 mmol) were added at 0°C. The reaction mixture was stirred at room temperature for 18 h. The solvent was removed under vacuum, the crude product was dissolved in ethyl acetate. The organic phase was washed with brine, dried over sodium sulfate and concentrated under vacuum. The crude product was used in the next step without any purification.

**Intermediate 28a**

Intermediate 27a (25g) was dissolved in 125 ml of dry tetrahydrofuran and the reaction mixture was cooled to 0°C. 350 ml of a cooled 0.5 M solution of (pent-4-enyl)magnesium bromide (Liebigs Annalen der Chemie 1982, 1478) was added and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was quenched with a saturated aqueous ammonium chloride solution. The organic phase was separated, dried over sodium
sulfate and concentrated under vacuum. The crude product was purified by flash chromatography to give 25g of the desired product.

**Intermediate 29a**

Intermediate 28a was added dropwise to a suspension of (S,S)-teth-TsDpen ruthenium chloride (20 mg, 0.032 mmol; Johnson Matthey Catalysts) in 200 ml formic acid/triethylamine complex under argon atmosphere. The reaction mixture was warmed to 70°C for 18 h. Then, water was added and the reaction mixture was extracted with diethyl ether. The organic phase was separated, dried over sodium sulfate and concentrated under vacuum. The crude product (40 g) was used in the next step without any purification.


The following intermediates were synthesized in analogy to Intermediates 27a, 28a and 29a.

<table>
<thead>
<tr>
<th>Starting Benzoyl chloride</th>
<th>Source</th>
<th>Amide Intermediate</th>
<th>Ketone Intermediate</th>
<th>Alcohol Intermediate</th>
<th>Stereochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-methyl-benzoyl chloride</td>
<td>Commercially available</td>
<td>27b</td>
<td>28b</td>
<td>29b</td>
<td>in analogy to Organic Letters <strong>2000</strong>, 1749-51</td>
</tr>
</tbody>
</table>
Intermediate 30a

To a suspension of sodium bicarbonate (40.6 g, 482 mmol) in 600 ml of acetonitrile, a solution of Intermediate 29a (40 g) in 100 ml of acetonitrile was added, followed by the addition of iodine (122 g, 482 mmol). The reaction mixture was stirred at room temperature for 1 h, then 1000 ml of a saturated aqueous Na$_2$S$_2$C${}_3^-$ solution were added. The mixture was extracted with diethyl ether. Then, the organic phase was separated, dried over sodium sulfate and concentrated under vacuum. The crude product was purified by flash chromatography to yield 29 g of the desired cis stereoisomer. Relative stereochemistry was assigned by 1H-NMR.

Intermediate 31a

Commercially available phthalimide potassium salt (17.4 g, 94.0 mmol) was added to a solution of Intermediate 30a (29 g, 78.4 mmol) in 250 ml DMF. The reaction mixture was stirred at 90°C for 18 h. The reaction mixture was concentrated under vacuum, diethyl ether was added and the organic phase was washed with an aqueous 1 M sodium hydroxide solution. The organic layer was separated, dried over sodium sulfate and concentrated under vacuum. The crude product (28.7g) was re-crystallised using 350 ml of methylcyclohexane. 9.5 g of enantiomerically enriched product were obtained.
Enantiomeric purity was determined by chiral HPLC (Method 2Ja):
\[ R_t \text{ (preferred stereoisomer)} = 6.69 \text{ min} \]
\[ R_t \text{ (second stereoisomer)} = 6.00 \text{ min} \]

Repeated re-crystallisations with methylcyclohexane allowed to increase the yield of the enantiopure preferred stereoisomer.

The following intermediates were synthesized in analogy to Intermediates 30a and 31a.

<table>
<thead>
<tr>
<th>synthesis in analogy to intermediate 30a</th>
<th>synthesis in analogy to intermediate 31a</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Starting Intermediate</strong></td>
<td><strong>Iodo Intermediate</strong></td>
</tr>
<tr>
<td>29b</td>
<td>30b</td>
</tr>
</tbody>
</table>

**Structure**

<table>
<thead>
<tr>
<th>Ptalimide Intermediate</th>
<th><strong>STRUCTURE</strong></th>
<th>Chiral HPLC method</th>
</tr>
</thead>
<tbody>
<tr>
<td>31b</td>
<td><img src="structure1.png" alt="Structure" /></td>
<td>Method 2a</td>
</tr>
<tr>
<td>29c</td>
<td><img src="structure2.png" alt="Structure" /></td>
<td>Method 2a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Rt (min)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>6.27 (preferred stereoisomer)</td>
</tr>
<tr>
<td>5.62 (second stereoisomer)</td>
</tr>
<tr>
<td>6.14 (preferred stereoisomer)</td>
</tr>
<tr>
<td>5.64 (second stereoisomer)</td>
</tr>
</tbody>
</table>
Intermediate 17b

Ethanolamine (8.84 ml, 146.4 mmol) was added to a solution of Intermediate 31a (9.5 g, 24.4 mmol) in 100 ml of toluene. The reaction mixture was stirred at 70°C for 3 h. Then, the mixture was cooled to room temperature and diluted with water and ethyl acetate. The organic phase was separated and washed with an aqueous 1M solution of sodium hydroxide, dried over sodium sulfate and concentrated under vacuum to give the desired product (6.1 g). The crude product was used in the next step without any purification.

The following intermediates were synthesized in analogy to Intermediate 29a.

<table>
<thead>
<tr>
<th>Starting Intermediate</th>
<th>Amine Intermediate</th>
<th>STRUCTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>31b</td>
<td>18a</td>
<td><img src="image" alt="Structure" /></td>
</tr>
<tr>
<td>31c</td>
<td>17c</td>
<td><img src="image" alt="Structure" /></td>
</tr>
</tbody>
</table>

Intermediate 32a

A solution of commercially available 2-(diethoxy-phosphoryl)-propionic acid ethyl ester (100 ml, 462 mmol) in 200 ml THF was added to a suspension of sodium hydride (18.5 g of a 60%
suspension on mineral oil, 462 mmol) in 800 ml THF at 0°C and stirred for 1 h. Then, commercially available dimethoxy-acetaldehyde (142 ml, 554 mmol) was added and the mixture was stirred for 30 min at 0°C. The solvent was removed and the residue was purified by chromatography to give the desired product (36.9 g, 196 mmol).

**Intermediate 32b**

![Intermediate 32b](attachment:image)

Commercially available 1-triphenylphosphoranylidene-2-propanone (32 g, 100 mmol) and methylpyruvate (15 ml, 150 mmol) were refluxed in 300 ml toluene for 2 days. The solvent was removed and the residue was dissolved in diisopropylether. The mixture was filtered. The solvent was removed in vacuum to give the desired product (15.1 g, 100 mmol).

**Intermediate 33a**

![Intermediate 33a](attachment:image)

Intermediate 32a (36.9 g, 196 mmol) was reacted with bromine (11 ml, 215 mmol) for six days at room temperature to give the crude product (58.3 g, 196 mmol) which was used in the next step without purification.

**Intermediate 33b**

![Intermediate 33b](attachment:image)

Was prepared in analogy to intermediate 33a starting from intermediate 32b.

**Intermediate 34a**

![Intermediate 34a](attachment:image)

Hydrazine hydrate (22.6 ml, 252 mmol) was added to a solution of intermediate 33a (56.3 g, 190 mmol) in 340 ml acetic acid. The reaction mixture was heated at 150°C overnight. The
solvent was removed in vacuum and the residue was purified by chromatography to give the desired product (20.9 g, 111 mmol).

**Intermediate 34b**

![Diagram of Intermediate 34b]

Was prepared in analogy to intermediate 34a starting from intermediate 33b.

**Intermediate 23a**

![Diagram of Intermediate 23a]

Intermediate 34a (5.0 g, 22.5 mmol) was added to phosphoryl chloride (5 ml) and the reaction mixture was refluxed for 1 h. The reaction mixture was poured onto ice water and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate and concentrated under vacuum to give the desired product (4.56 g, 22.4 mmol) which was used in the next step without purification.

**Intermediate 23b**

![Diagram of Intermediate 23b]

Was prepared in analogy to intermediate 23a starting from intermediate 34b.

**Intermediate 24g**

![Diagram of Intermediate 24g]

A mixture of intermediate 23a (53 mg, 325 µmol), 4-tert-butyl-benzylamine (53 µl, 325 µmol) and N,N-diisopropylethylamine (240 µl, 1.3 mmol) in 2 ml NMP was heated to 120°C for 3 h. The mixture was cooled to room temperature and then directly purified by reversed phase HPLC to give the desired product (22 mg, 54 µmol).
Intermediate 24m

A mixture of intermediate 23a (500 mg, 3.1 mmol), commercially available 3,4-dichloro-aniline (497 mg, 3.1 mmol) and 1 ml concentrated hydrochloric acid in 8 ml water was heated in a microwave vial to 160°C for 1 h. The mixture was concentrated under vacuum and then purified by reversed phase HPLC to give the desired product (174 mg, 603 µmol).

Intermediate 26g

A mixture of intermediate 24g (22 mg, 54 µmol), palladium acetate (1.2 mg, 5 µmol), 1,1'-bis(diphenylphosphino)-ferrocene (3 mg, 5 µmol), sodium acetate (13 mg, 163 µmol) in 5 ml methanol and 5 ml DMF was stirred under a carbon monoxide atmosphere (5 bar) for 48 h at 70°C. The mixture was filtered and concentrated in vacuum. The residue was purified by reversed phase HPLC to give the corresponding ester (23 mg, 54 µmol).

Lithium hydroxide (9 mg, 215 µmol) was added to a solution of the ester (23 mg, 54 µmol) in 2 ml THF and 2 ml water. The reaction mixture was stirred for 15 min at 100°C and then concentrated under vacuum. The residue was purified by reversed phase HPLC to give the desired product (3 mg, 7 µmol).

The following intermediates were synthesized in analogy to intermediates 24g and 26g starting from intermediate 23a:
<table>
<thead>
<tr>
<th>Starting amine</th>
<th>Cl-pyridazine intermediate</th>
<th>Structure</th>
<th>Acid intermediate</th>
<th>Structure</th>
<th>Stereochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>24h</td>
<td><img src="image1.png" alt="Image" /></td>
<td>26h</td>
<td><img src="image2.png" alt="Image" /></td>
<td>as shown</td>
</tr>
<tr>
<td>7-Fluorotetrahydro-isoquinoline</td>
<td>24i</td>
<td><img src="image3.png" alt="Image" /></td>
<td>26i</td>
<td><img src="image4.png" alt="Image" /></td>
<td>as shown</td>
</tr>
<tr>
<td>17c</td>
<td>24j</td>
<td><img src="image5.png" alt="Image" /></td>
<td>26j</td>
<td><img src="image6.png" alt="Image" /></td>
<td>relative stereochemistry cis</td>
</tr>
<tr>
<td>18a</td>
<td>24k</td>
<td><img src="image7.png" alt="Image" /></td>
<td>26k</td>
<td><img src="image8.png" alt="Image" /></td>
<td>as shown</td>
</tr>
</tbody>
</table>
The following intermediates were synthesized in analogy to intermediates 24g and 26g starting from intermediate 23b:

<table>
<thead>
<tr>
<th>Starting amine</th>
<th>Cl-pyridazine intermediate</th>
<th>STRUCTURE</th>
<th>Acid intermediate</th>
<th>STRUCTURE</th>
<th>Stereochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-tert-butyl-benzylamine</td>
<td>24n</td>
<td><img src="image" alt="Structure 24n" /></td>
<td>26n</td>
<td><img src="image" alt="Structure 26n" /></td>
<td></td>
</tr>
</tbody>
</table>

**SYNTHESIS OF EXAMPLES**

The examples of this invention are synthesized according to the following general synthetic procedures:
Synthetic Procedure:

Example 1

Intermediate 26a (24 mg, 54 µmol), TBTU (22 mg, 68 µmol) and N,N-diisopropylethylamine (76 µl, 433 µmol) were dissolved in 1 ml DMF. Then, intermediate 20a (34 mg, 123 µmol) was added and the reaction mixture was stirred for 2 h. The reaction mixture was diluted with dichloromethane and washed with an aqueous saturated sodium bicarbonate solution. The organic layer was dried over sodium sulfate and concentrated in vacuum. The residue was purified by reversed phase HPLC to give the desired product (37 mg, 53 µmol).

HPLC (Method 2Cc): R_t (min) = 1.19

[M+H]^+ = 587

The following examples were synthesized in analogy to the preparation of Example 1.

<table>
<thead>
<tr>
<th>Ex #</th>
<th>STRUCTURE</th>
<th>Intermediate</th>
<th>Amine</th>
<th>HPLC R_t (min)</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td><img src="structure.png" alt="Structure" /></td>
<td>26a</td>
<td>20d</td>
<td>1.20</td>
<td>2Cc</td>
</tr>
</tbody>
</table>

[M+H]^+ = 587
<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td><img src="image" alt="Chemical Structure" /></td>
<td>26b</td>
<td>20c</td>
<td>552</td>
<td>1.90</td>
</tr>
<tr>
<td>4</td>
<td><img src="image" alt="Chemical Structure" /></td>
<td>26c</td>
<td>20c</td>
<td>564</td>
<td>1.99</td>
</tr>
<tr>
<td>5</td>
<td><img src="image" alt="Chemical Structure" /></td>
<td>26d</td>
<td>20c</td>
<td>638</td>
<td>1.96</td>
</tr>
<tr>
<td>6</td>
<td><img src="image" alt="Chemical Structure" /></td>
<td>26e</td>
<td>20b</td>
<td>568</td>
<td>1.83</td>
</tr>
<tr>
<td>7</td>
<td><img src="image" alt="Chemical Structure" /></td>
<td>26f</td>
<td>20c</td>
<td>622</td>
<td>2.012</td>
</tr>
<tr>
<td>8</td>
<td><img src="image" alt="Chemical Structure" /></td>
<td>26f</td>
<td>20b</td>
<td>622</td>
<td>1.970</td>
</tr>
<tr>
<td>9</td>
<td><img src="image" alt="Chemical Structure" /></td>
<td>26g</td>
<td>20d</td>
<td>496</td>
<td>1.088</td>
</tr>
<tr>
<td></td>
<td>Chemical Structure</td>
<td>Code</td>
<td>Temperature</td>
<td>Melting Point</td>
<td>Property</td>
</tr>
<tr>
<td>---</td>
<td>-------------------</td>
<td>-------</td>
<td>-------------</td>
<td>---------------</td>
<td>----------</td>
</tr>
<tr>
<td>10</td>
<td><img src="image1" alt="Chemical Structure" /></td>
<td>26h</td>
<td>20c</td>
<td>522</td>
<td>1.785</td>
</tr>
<tr>
<td>11</td>
<td><img src="image2" alt="Chemical Structure" /></td>
<td>26i</td>
<td>20c</td>
<td>534</td>
<td>1.760</td>
</tr>
<tr>
<td>12</td>
<td><img src="image3" alt="Chemical Structure" /></td>
<td>26j</td>
<td>20c</td>
<td>608</td>
<td>1.339</td>
</tr>
<tr>
<td>13</td>
<td><img src="image4" alt="Chemical Structure" /></td>
<td>26k</td>
<td>20e</td>
<td>526</td>
<td>0.944</td>
</tr>
<tr>
<td>14</td>
<td><img src="image5" alt="Chemical Structure" /></td>
<td>26j</td>
<td>20e</td>
<td>596</td>
<td>1.200</td>
</tr>
<tr>
<td>15</td>
<td><img src="image6" alt="Chemical Structure" /></td>
<td>26l</td>
<td>20b</td>
<td>592</td>
<td>1.820</td>
</tr>
<tr>
<td>16</td>
<td><img src="image7" alt="Chemical Structure" /></td>
<td>26l</td>
<td>20e</td>
<td>592</td>
<td>1.828</td>
</tr>
<tr>
<td>17</td>
<td><img src="image" alt="Chemical Structure 17" /></td>
<td>26i</td>
<td>20b</td>
<td>534</td>
<td>1.760</td>
</tr>
<tr>
<td>18</td>
<td><img src="image" alt="Chemical Structure 18" /></td>
<td>26h</td>
<td>20c</td>
<td>510</td>
<td>0.999</td>
</tr>
<tr>
<td>19</td>
<td><img src="image" alt="Chemical Structure 19" /></td>
<td>26i</td>
<td>20c</td>
<td>580</td>
<td>1.032</td>
</tr>
<tr>
<td>20</td>
<td><img src="image" alt="Chemical Structure 20" /></td>
<td>26i</td>
<td>20c</td>
<td>522</td>
<td>0.957</td>
</tr>
<tr>
<td>21</td>
<td><img src="image" alt="Chemical Structure 21" /></td>
<td>26m</td>
<td>20c</td>
<td>482</td>
<td>0.873</td>
</tr>
<tr>
<td>22</td>
<td><img src="image" alt="Chemical Structure 22" /></td>
<td>26m</td>
<td>20c</td>
<td>494</td>
<td>0.889</td>
</tr>
<tr>
<td>23</td>
<td><img src="image" alt="Chemical Structure 23" /></td>
<td>26n</td>
<td>20d</td>
<td>510</td>
<td>1.340</td>
</tr>
</tbody>
</table>
Claims

1. Compounds according to formula (I),

![Chemical Structure (I)](image)

wherein

- A is a group selected from among \(-\text{NH-L}_1\text{-R}_7\), \(-\text{NCH}_3\text{-L}_1\text{-R}_7\), \(-\text{O-L}_1\text{-R}_7\), and the structure (II)

![Chemical Structure (II)](image)

wherein \(\text{L}_i\) is a linker selected from a bond or a group selected from among
- \(-\text{Ci-C}_2\text{-alkylene}\), and \(-\text{Ci-C}_2\text{-alkenylene}\) which optionally comprises one or more groups selected from \(-\text{O}\), \(-\text{C(O)}\), and \(-\text{NH}\) in the chain and which is optionally substituted by a group selected from among \(-\text{OH}\), \(-\text{NH}_2\), \(-\text{Ci-C}_3\text{-alkyl}\), \(-\text{O-Ci-C}_3\text{-alkenyl}\), and \(-\text{CN}\),

wherein \(\text{R}_7\) is a ring selected from among \(-\text{C}_3\text{-C}_8\text{-cycloalkyl}\), \(-\text{C}_3\text{-C}_8\text{-heterocyclyl}\), \(-\text{C}_5\text{-Ci-aryl}\), and \(-\text{Cs-Ci-heteroaryl}\),

where the the ring \(\text{R}_7\) is optionally substituted with one or more groups selected from among \(-\text{CF}_3\), \(-\text{Ci-Cg-alkyl}\), \(-\text{O-CF}_3\), \(-\text{CN}\), \(-\text{O-Ci-Cg-alkyl}\), \(-\text{Ci-Cg-alkenyl}\), and \(-\text{Ci-Cg-alkynyl}\), and \(-\text{halogen}\),

or wherein the ring \(\text{R}_7\) is optionally substituted with one or more groups selected from among \(-\text{C}_5\text{-C}_{10}\text{-aryl}\), \(-\text{Cs-Ci-heteroaryl}\), \(-\text{C}_3\text{-C}_8\text{-cycloalkyl}\), \(-\text{C}_3\text{-Cs-heterocyclyl}\), optionally being substituted by one or more groups selected from among \(-\text{OH}\), \(-\text{NH}_2\), \(-\text{Ci-C}_4\text{-alkyl}\), \(-\text{O-Ci-Cg-alkyl}\), \(-\text{CN}\), \(-\text{CF}_3\), \(-\text{OCF}_3\), \(-\text{halogen}\), and \(-\text{O}\),

or wherein the ring \(\text{R}_7\) is optionally further bi-valently substituted on two neighbouring ring atoms, such that an annellated ring is formed by one or more groups selected from among \(-\text{Ci-C}_6\text{-alkylene}\), \(-\text{C}_2\text{-C}_6\text{-alkenylene}\) and \(-\text{C}_4\text{-C}_6\text{-alkynylene}\), in which one or two carbon centers may optionally be replaced by 1 or 2 hetero atoms selected from N, O and S, the bivalent group being optionally substituted by one or
more groups selected from -OH, -NH₂, -C₃H₆-alkyl, -0-C₆H₃-alkyl, -CN, -CF₃,
-OCF₃, halogen, and =0;

wherein R₆ is selected from among -H, -halogen, -CN, -0-C₄H₃-alkyl, -Ci-C₄-alkyl,
-CH=CH₂, -C≡CH, -CF₃, -OCF₃, -OCF₂H, and -OCF₂H₂;

wherein R₂ is selected from among -H, -halogen, -CN, -0-C₄H₃-alkyl, -Ci-C₄-alkyl,
-CH=CH₂, -C≡CH, -cyclopropyl, -CF₃, -OCF₃, -OCF₂H, and -OCF₂H₂;

wherein R₃ is selected from among -H, -methyl, -ethyl, -propyl, -i-propyl,
cylopropyl, -OCH₃, -OH, and -CN;

wherein Z is C or N;

wherein Rᵢ is selected from among -H, -Ci-C₄-alkyl, -OH, -0-Ci-C₄-alkyl, -halogen,
-CN, -CF₃, and -OCF₃;

wherein n is 1, 2 or 3;

wherein R₄ and R₅ are independently selected from among an electron pair, -H, and a
group selected from among -Ci-C₆H₃-alkyl, -NH₂, -C₃H₆-cycloalkyl, -C₃H₆-heterocyclyl,
-C₅H₁₀-aryl, -C₆H₄-heteroary, and -C(0)-N(R₈,Rₛ'), with R₈ and Rs' independently being selected from among -H, and -Ci-C₆-alkyl,
and wherein R₄ and R₅ if different from an electron pair or -H are optionally
independently substituted with one or more groups selected from among -halogen,
-OH, -CF₃, -CN, -Ci-C₆-alkyl, -0-Ci-C₆-alkyl, -0-C₃H₆-cycloalkyl,
-0-C₃H₆-heterocyclyl, -0-C₅H₁₀-aryl, -0-C₆H₄-heteroary, -Co-C₆-alkylene-CN,
-Co-C₄-alkylene-0-Ci-C₄-alkyl, -Co-C₄-alkylene-0-C₃H₈-cycloalkyl,
-Co-C₄-alkylene-0-C₃H₈-heterocyclyl, -Co-C₄-alkylene-0-C₅H₁₀-aryl,
-Co-C₄-alkylene-0-C₅H₁₀-heteroary, -C₀₄-C₄-alkylene-Q-Co-C₄-alkyl-N(R₉,R₀),
-Co-C₄-alkylene-N(Rio)Q-Co-C₄-alkyl, -Co-C₄-alkylene-N(Rio)Q-C₃H₆-cycloalkyl,
-Co-C₄-alkylene-N(Rio)Q-C₅H₁₀-heterocyclyl, -Co-C₄-alkylene-N(Rio)Q-C₆H₄-heteroary,
-Co-C₄-alkylene-N(Rio)Q-C₅H₁₀-heteroary, -Co-C₆H₄-alkylene-Q-N(Rᵣ,Rᵢᵣ),
-Co-C₆H₄-alkylene-N(Rᵢᵣ)Q-N(Rᵣ,Rᵢᵣ), -Co-C₆H₄-alkylene-Rᵣ₄,
-Co-C₆H₄-alkylene-Q-C₂H₆-alkyl, -Co-C₆H₄-alkylene-Q-C₂H₆-cycloalkyl,
-Co-C₆H₄-alkylene-Q-C₃H₈-cycloalkyl, -Co-C₆H₄-alkylene-Q-C₅H₁₀-aryl,
-Co-C₆H₄-alkylene-Q-C₅H₁₀-heteroary, -Co-C₆H₄-alkylene-Q-N(Rᵢ₅,Rᵢ₅'),
-and Co-C₆H₄-alkylene-N(Rᵢ₆)Q-0-(Rᵢ γ),
wherein Q is selected from among -C(O)₂⁻, and -SO₂⁻.
wherein \( R_{i2}, R_{i6} \) are independently selected from among \(-H, -\text{Ci-C}_6\text{-alkyl}, \text{and} -\text{C}_3\text{-C}_6\text{-cycloalkyl}, \)
wherein \( R_{o}, R_{o}', R_{i0}, R_{i1}, R_{i3}, R_{i3}', R_{i5}, \) are independently selected from among \(-H, -\text{Ci-C}_6\text{-alkyl}, \text{and} -\text{C}_3\text{-C}_6\text{-cycloalkyl}, \)
or wherein \( R_{o} \text{ and } R_{o}' \), \( R_{i1} \text{ and } R_{i3} \), \( R_{i5} \) and \( R_{i5}' \) together form a \(-\text{C}_2\text{-C}_6\text{-alkylene group}, \)
wherein \( R_{i4} \) and \( R_{i17} \) are independently selected from among \(-H, -\text{Ci-C}_6\text{-alkyl}, \text{and} -\text{C}_5\text{-C}_io\text{-ary1}, -\text{Cs-Cio-heteroaryl}, -\text{C}_3\text{-Cs-cycloalkyl}, \text{and} -\text{Cs-Cs-heterocyclyl}, \)
wherein \( -\text{Cs-cycloalkyl}, \text{and} -\text{Cs-heterocyclyl}, \)
wherein \( R_{i8} \) is optionally substituted by one or more groups selected from among halogen, \(-\text{CF}_3, -\text{OCF}_3, -\text{CN}, -\text{OH}, -\text{O-Ci-C}_g\text{-alkyl}, -\text{Ci-Cg-alkyl}, \text{and} -\text{C}_3\text{-C}_i\text{-cycloalkyl}, \text{and} -\text{C}_3\text{-Cs-heterocyclyl}, \)
wherein \( R_{i8} \) is optionally substituted by one or more groups selected from among halogen, \(-\text{CF}_3, -\text{OCF}_3, -\text{CN}, -\text{OH}, -\text{O-Ci-C}_g\text{-alkyl}, -\text{Ci-Cg-alkyl}, \text{and} -\text{C}_3\text{-C}_i\text{-cycloalkyl}, \text{and} -\text{C}_3\text{-Cs-heterocyclyl}, \)
wherein \( R_{i8} \) is optionally substituted by one or more groups selected from among halogen, \(-\text{CF}_3, -\text{OCF}_3, -\text{CN}, -\text{OH}, -\text{O-Ci-C}_g\text{-alkyl}, -\text{Ci-Cg-alkyl}, \text{and} -\text{C}_3\text{-C}_i\text{-cycloalkyl}, \text{and} -\text{C}_3\text{-Cs-heterocyclyl}, \)
and wherein \( R_{i4}, R_{i5} \) and \( R_{i8} \) are optionally further substituted by spiro-\(\text{C}_3\text{-Cs-cycloalkyl or spiro-\(\text{C}_3\text{-c8}\text{-heterocyclic such that together with } R_{i4}, R_{i5} \text{ and/or } R_{i8} \text{ a spirocycle is formed, wherein spiro-\(\text{C}_3\text{-Cs-heterocyclyl optionally comprises one or more groups selected from among nitrogen, } -\text{C(O)}-, -\text{S0}_2\text{-, and } -\text{N(S0}_2\text{-Ci-C}_4\text{-alkyl)- in the ring,} \)
or wherein \( R_{i4}, R_{i5} \) and \( R_{i8} \) are optionally further bi-valently substituted by one or more spirocyclic or annelated ring forming groups selected from among \(-\text{Ci-C}_6\text{-alkylene, -C}_2\text{-C}_6\text{-alkynylene, and -C}_4\text{-C}_6\text{-alkynylene, in which one ore two carbon centers may optionally be replaced by one or two hetero atoms selected from among N, O and S and which may optionally be substituted by one or more groups on one ring atom or on two neighbouring ring atoms selected from among -OH, -NH}_2, -\text{Ci-C}_5\text{-alkyl, O-Ci-Cg-alkyl, -CN, -CF}_3, -\text{OCF}_3, \text{and halogen;}} \)
as well as in form of their acid addition salts with pharmacologically acceptable acids.
2. The compounds of claim 1, wherein A is a group selected from among -NH-L1-R7, -O-L1-R7, and the structure (II)

\[
\begin{align*}
\text{R}_6 & = \text{N}^* \\
\end{align*}
\]

(II)

wherein \( L_i \) is a linker selected from a bond or a group selected from among -Ci-C2 -alkylene,
wherein \( R_7 \) is a ring selected from among -C3-C8-cycloalkyl, -C3-C8-heterocyclyl, and -C5-C10-aryl,
wherein the ring \( R_7 \) is optionally substituted with one or more groups selected from among -CF3, -C6-alkyl, and -O-CF3,
or wherein the ring \( R_7 \) is optionally substituted with one or more groups selected from among -C5-Cio-aryl, optionally being substituted by one or more groups selected from among -Ci-C4 -alkyl, and -OCF3;

wherein \( R_6 \) denotes -CF3;

wherein \( R_2 \) is selected from among -H, -Ci-C4 -alkyl, and -CF3;

wherein \( R_3 \) is selected from among -H, -OCH3, and -OH;

wherein Z denotes C;

wherein \( R_i \) denotes -H;

wherein n is 2;

wherein \( R_4 \) denotes -H, and \( R_5 \) is a group selected from -C3-C8-heterocyclyl, and wherein \( R_5 \) is optionally substituted with one or more groups selected from among -Co-C4-alkylene-N(Rio)-Q-Ci-C4-alkyl,
wherein Q is denotes -S02, and wherein Rio. is selected from among -H, and -Ci-C6 -alkyl,
or wherein \( R_4 \) denotes -H, and \( R_5 \) is selected from a group of the structure -L2-Ris.
wherein \( L_2 \) denotes -NH- and wherein \( R_{i_3} \) is selected from among -C\(_3\)-C\(_8\) -heterocyclyl, wherein \( R_{i_3} \) is optionally substituted by one or more groups selected from among -0-C\(_i\)-C\(_4\)-alkyl.

3. The compounds of claim 1, wherein \( A \) is -NH-L\(_1\)-R\(_7\), and wherein \( L_i \) is a bond or wherein \( L_i \) denotes methylene, and wherein \( R_7 \) is a ring selected from among -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, -cycloheptyl, -pyrrolidinyl, -piperidinyl, -azepanyl, -tetrahydrofuranyl, -tetrahydropyranyl, -oxepanyl, -phenyl, -pyridyl, and -furanyl, wherein the ring \( R_7 \) is optionally substituted with one or more groups selected from among -F, -Cl, -methyl, -ethyl, -propyl, -i-propyl, -cyclopropyl, -t-butyl, -CF\(_3\), -O-CF\(_3\), -CN, -O-methyl, -furanyl and -phenyl, wherein said -phenyl is optionally independently substituted by one or more groups selected from among -Ci-C\(_4\)-alkyl, halogen, -OCH\(_3\), -CF\(_3\), and -OCF\(_3\).

4. The compounds of claims 1 or 2, wherein \( A \) is -NH-Li-R\(_7\), and wherein \( L_i \) is a bond or wherein \( L_i \) denotes methylene, and wherein \( R_7 \) is a ring selected from among among -C\(_3\)-Cs-heterocyclyl, and -C\(_5\)-C\(_{10}\)-aryl, wherein the ring \( R_7 \) is optionally substituted with one or more groups selected from among -0-CF\(_3\), -Ci-C\(_6\)-alkyl, or wherein the ring \( R_7 \) is optionally substituted with one or more groups selected from -phenyl, optionally being substituted by one or more groups selected from -Ci-C\(_4\)-alkyl, and -OCF\(_3\).

5. The compounds of claims 1 or 2, wherein \( A \) denotes a group selected from among formula (III)

![Formula (III)](attachment)

wherein \( R_{i_9} \) denotes the ring -C\(_5\)-C\(_{10}\)-aryl, wherein the ring \( R_{i_9} \) is optionally substituted with one or more groups selected from among -0-CF\(_3\), and -Ci-C\(_6\)-alkyl, preferably by a group selected from among -0-CF\(_3\).
6. The compounds of claims 1 or 2, wherein A is a group selected from among formula (IV) and (V)

\[
\begin{align*}
\text{(IV), and} & \text{ (V),} \\
R_{19}^i & \text{(IV),} \quad \text{and} \quad R_{19}^i & \text{(V),}
\end{align*}
\]

wherein R_{19}^i is selected from among -H, -O-CF_3, and -C_6-alkyl.

5

7. The compounds of any of the preceding claims, wherein R_2 is selected from among -H, -CF_3, and -CH_3, preferably selected from -CH_3.

8. The compounds of any of the preceding claims, wherein R_3 is selected from among -H, -OCH_3, and -methyl, preferably selected from -OCH_3.

9. The compounds of any of the preceding claims wherein R_i is selected from among -H, and -CH_3, preferably wherein R_i denotes -H.

10. The compounds of any of the preceding claims, wherein R_4 denotes -H.

11. The compounds of any of the preceding claims, wherein n is 2.

12. The compounds of any of the preceding claims, wherein Z denotes C.

13. The compounds of any of the claims 1, 3-12, wherein Z denotes C, and wherein R_4 denotes -H, and wherein R_5 denotes a group of the structure -L_2-Ri_s,

\[
\begin{align*}
\text{wherein L}_2 & \text{ is a group selected from among -NH-, and -N(CH}_3^\text{)}, \\
R_{19}^i & \text{ is } -C_6^-\text{heterocycl cycl comprising 1 hetero atom selected from O,} \\
\text{wherein R}_{19}^i & \text{ is optionally substituted by -0-CH}_3^\text{;}
\end{align*}
\]

or wherein R_4 denotes -H and R_5 denotes a group of the structure -N(R_{21},R_{21}'),

\[
\begin{align*}
\text{wherein R}_{21}^\text{ and R}_{21}' & \text{ together form a } -C_4^-\text{-alkylene group such that a ring is} \\
\text{formed, wherein such ring is optionally substituted with one or more groups selected from among -OH, and -N(C}_0^-\text{-alkyl)-SO}_2^-\text{CH}_3\text{;}
\end{align*}
\]

or wherein R_4 denotes -H, and wherein R_5 denotes a group of the structure -N(R_{21},R_{21}'),

35
wherein R₂i and R₂r together form a -C₅-alkylene group such that a ring is formed, in which one carbon center of the -Cs-alkylene group is replaced by one hetero atom selected from O.

14. Use of a compound according to any of the preceding claims as a medicament.

15. Use of a compound of any of claims 1-13 for making a medicament for the treatment of inflammatory diseases.

16. Use according to claim 15, wherein the inflammatory diseases are selected from inflammatory diseases of the respiratory tract.

17. Use according to claim 16, wherein the diseases are selected from chronic obstructive pulmonary disease, asthma, and cystic fibrosis.


INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2011/058355

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D405/14 A61K31/5Q1 A61P11/00 A61P25/00 A61P13/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified).
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search
1 August 2011

Date of mailing of the international search report
09/08/2011

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016

Authorized officer
Hoepfner, Wolfgang
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CA 2648555 A</td>
<td>25-10-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101465677 A</td>
<td>24-06-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2013174 A2</td>
<td>14-01-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2009533435 A</td>
<td>17-09-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 200925885 1 A</td>
<td>15-10-2009</td>
</tr>
</tbody>
</table>